{"meta":{"query_hash":"d78694197d76","filters":{"venue":"Clinical Neuropharmacology"},"cohort_total":70,"direct_labels_cover":0,"predictions_cover":70,"exported":70,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/d78694197d76","api":"https://metacan.xera.ac/api/v1/cohort?venue=Clinical+Neuropharmacology"},"results":[{"id":"W117490009","doi":"10.1097/wnf.0b013e3181c46f48","title":"A Prospective, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Type A Botulinum Toxins Botox and Prosigne in the Treatment of Cervical Dystonia","year":2010,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cervical dystonia; Spasmodic Torticollis; Medicine; Tolerability; Randomized controlled trial; Botulinum toxin; Dystonia; Quality of life (healthcare); Adverse effect; Anesthesia; Torticollis; Rating scale; Surgery; Internal medicine; Psychology","score_opus":0.06563286935701265,"score_gpt":0.396070542860635,"score_spread":0.3304376735036223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W117490009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866279,0.002231337,0.0009567741,0.00022522768,0.0004882983,0.008053028,0.00042908866,0.000069522204,0.00091878034],"genre_scores_gemma":[0.9766226,0.002068257,0.0039139944,0.0010827646,0.00093422516,0.012765077,0.0007117836,0.000028763594,0.001872597],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99590826,0.0024557337,0.0004205777,0.00049751496,0.0003921124,0.00032573575],"domain_scores_gemma":[0.99441224,0.0023438232,0.0011116804,0.0005409895,0.0004540698,0.0011372262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054008774,0.0018493965,0.004763143,0.0007111829,0.0010972051,0.0011093044,0.0011221028,0.0029879017,0.0051153065],"category_scores_gemma":[0.006653572,0.0014225886,0.0017376018,0.00074943894,0.002883881,0.0014097086,0.0006030644,0.0024490594,0.00087476394],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9791444,0.012508305,0.0004751503,0.0002458476,0.0003810385,0.000024110064,0.000036172856,0.00010212607,0.0020193097,0.00005855693,0.00010016214,0.0049049184],"study_design_scores_gemma":[0.8613983,0.13687901,0.0009434254,0.000011815112,0.00019499946,0.000013687209,0.000009349171,0.000121168596,0.00023224924,0.000041028885,0.00014460525,0.000010350681],"about_ca_topic_score_codex":0.0007762767,"about_ca_topic_score_gemma":0.0011777943,"teacher_disagreement_score":0.0054008774,"about_ca_system_score_codex":0.00068411493,"about_ca_system_score_gemma":0.002578155,"threshold_uncertainty_score":0.028562903},"labels":[],"label_agreement":null},{"id":"W1824305151","doi":"10.1097/wnf.0b013e318059be76","title":"Add-on Therapy With Acetylcholinesterase Inhibitors for Memory Dysfunction in Schizophrenia","year":2007,"lang":"en","type":"review","venue":"Clinical Neuropharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Donepezil; Rivastigmine; Neurocognitive; Schizophrenia (object-oriented programming); Galantamine; Randomized controlled trial; Placebo; Memory impairment; Psychology; Medicine; Verbal memory; Meta-analysis; Clinical trial; Cognition; Dementia; Psychiatry; Internal medicine","score_opus":0.20501452474498705,"score_gpt":0.4969339128382372,"score_spread":0.29191938809325013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1824305151","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018404936,0.97477424,0.0004834097,0.0013591063,0.0005688673,0.001142637,0.0009054965,0.0000244357,0.0023368665],"genre_scores_gemma":[0.1850037,0.80386245,0.0033453256,0.0034108232,0.0008867562,0.0013184762,0.0014910286,0.000015856938,0.0006655282],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99464744,0.002465268,0.0016094119,0.00029109395,0.0008502377,0.00013651629],"domain_scores_gemma":[0.9891059,0.0067628026,0.0030237697,0.00025438858,0.00065788405,0.0001951665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009626953,0.00085482484,0.003767144,0.004902586,0.00033433086,0.0020553772,0.0011227347,0.0012382393,0.0063427067],"category_scores_gemma":[0.018196123,0.0005510944,0.0070298635,0.002616026,0.00064555847,0.001301209,0.0011035401,0.0012665023,0.00052792055],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01494678,0.00034173788,0.009738,0.6608227,0.054021303,0.0006591288,0.00022243222,0.00058026105,0.0027394015,0.00092483824,0.0040489496,0.2509545],"study_design_scores_gemma":[0.031057024,0.013060595,0.071193054,0.3811316,0.43807808,0.0040585566,0.000727933,0.00087985024,0.0033171827,0.0046310346,0.051574573,0.0002905866],"about_ca_topic_score_codex":0.0022466786,"about_ca_topic_score_gemma":0.008706021,"teacher_disagreement_score":0.009626953,"about_ca_system_score_codex":0.0017827003,"about_ca_system_score_gemma":0.002729514,"threshold_uncertainty_score":0.050912797},"labels":[],"label_agreement":null},{"id":"W1923911528","doi":"10.1097/wnf.0000000000000101","title":"A Comparison of Botox 100 U/mL and Dysport 100 U/mL Using Dose Conversion Ratio 1","year":2015,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Allergan; Ipsen","keywords":"Medicine; Cervical dystonia; Confidence interval; Spasmodic Torticollis; Randomized controlled trial; Anesthesia; Botulinum toxin; Significant difference; Crossover study; Surgery; Torticollis; Internal medicine","score_opus":0.2577468131499699,"score_gpt":0.4951198360469998,"score_spread":0.23737302289702988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1923911528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940661,0.0038591218,0.000548004,0.00007525317,0.00015430378,0.0007250986,0.00007649489,0.000025251504,0.00047035006],"genre_scores_gemma":[0.99321777,0.0023755196,0.002449938,0.00016939647,0.00015071996,0.0008177016,0.00018608096,0.000010118835,0.0006226307],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9980804,0.0010087196,0.00019469546,0.00026303536,0.00033733895,0.00011586072],"domain_scores_gemma":[0.99862933,0.00054313714,0.00048543283,0.00010030282,0.00010686174,0.00013492703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002093373,0.00065818446,0.0016984823,0.0006428491,0.00017912974,0.00058325205,0.0007304609,0.0012544099,0.0021228823],"category_scores_gemma":[0.0025754783,0.0005264435,0.0011571143,0.00041876797,0.00071521645,0.0007026089,0.00029756784,0.0007475505,0.0003126486],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84263426,0.012799209,0.0016255378,0.0015132183,0.0012137375,0.00009211923,0.00019457967,0.000583305,0.06981193,0.00036271755,0.00033594295,0.068833426],"study_design_scores_gemma":[0.17510936,0.805515,0.0068903477,0.00008488295,0.001267853,0.0001436377,0.000059575967,0.0006329487,0.009009155,0.00011637451,0.0011342211,0.00003661883],"about_ca_topic_score_codex":0.00034741222,"about_ca_topic_score_gemma":0.00043848736,"teacher_disagreement_score":0.0021228823,"about_ca_system_score_codex":0.00048523952,"about_ca_system_score_gemma":0.00049380405,"threshold_uncertainty_score":0.011070967},"labels":[],"label_agreement":null},{"id":"W1963544666","doi":"10.1097/wnf.0b013e31819a68b5","title":"Effectiveness of Switching to Aripiprazole From Atypical Antipsychotics in Patients With Schizophrenia","year":2009,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Otsuka Pharmaceutical","keywords":"Aripiprazole; Schizophrenia (object-oriented programming); Positive and Negative Syndrome Scale; Neurocognitive; Wisconsin Card Sorting Test; Psychology; Brief Psychiatric Rating Scale; Akathisia; Rating scale; Scale for the Assessment of Negative Symptoms; Psychiatry; Cognition; Trail Making Test; Global Assessment of Functioning; Clinical psychology; Psychosis; Antipsychotic; Neuropsychology; Developmental psychology","score_opus":0.02359581114582315,"score_gpt":0.3757193929095006,"score_spread":0.3521235817636775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963544666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991696,0.0004982753,0.000014396705,0.00004388259,0.000011459167,0.000013384033,0.000043729975,0.0000037261088,0.00020162691],"genre_scores_gemma":[0.9994199,0.00021644217,0.00005350345,0.00007882098,0.000020668396,0.000012605031,0.00013632701,8.201824e-7,0.000060984676],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996388,0.00011216517,0.000058255155,0.000053476597,0.0000895281,0.000047821184],"domain_scores_gemma":[0.9987913,0.0003244547,0.0004106999,0.000053151885,0.00009591549,0.00032450978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005892591,0.00030157168,0.0008067971,0.00023164842,0.000413103,0.00044847612,0.00022547976,0.00053012714,0.00092835736],"category_scores_gemma":[0.0029585273,0.000174718,0.000608723,0.00021255027,0.00019972419,0.00041525718,0.00019524418,0.00051614066,0.00012891772],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06710613,0.004850136,0.7499019,0.00040236066,0.0016683543,0.00093614834,0.0007159527,0.00094985234,0.010635499,0.000029545683,0.0006103578,0.1621937],"study_design_scores_gemma":[0.0024801327,0.021174297,0.97296304,0.0000534989,0.00045271686,0.00066002435,0.00029057058,0.0006795813,0.00062581216,0.000041703704,0.00055058213,0.000028004499],"about_ca_topic_score_codex":0.0016138324,"about_ca_topic_score_gemma":0.0034568468,"teacher_disagreement_score":0.0016138324,"about_ca_system_score_codex":0.00047189245,"about_ca_system_score_gemma":0.0003984322,"threshold_uncertainty_score":0.00342381},"labels":[],"label_agreement":null},{"id":"W1970671532","doi":"10.1097/00002826-200309000-00004","title":"Poor Tolerability of a Transdermal Nicotine Treatment in Parkinson's Disease","year":2003,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Nicotinic Acetylcholine Receptors Study","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Montréal; Hôtel-Dieu de Québec; Université du Québec à Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Tolerability; Transdermal; Medicine; Nicotine; Nausea; Vomiting; Adverse effect; Anesthesia; Parkinson's disease; Pharmacology; Internal medicine; Disease","score_opus":0.031157462677720807,"score_gpt":0.36045654070042094,"score_spread":0.32929907802270014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970671532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99423593,0.0036766874,0.0006153691,0.00022342715,0.000020927726,0.00004596201,0.00009100696,0.000020964102,0.001069643],"genre_scores_gemma":[0.9987087,0.00059033965,0.00019560497,0.00014260547,0.000028642637,0.000017094331,0.00008403042,0.000003855617,0.00022911782],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9993325,0.00029429322,0.00009710129,0.000055481145,0.00019133593,0.00002934839],"domain_scores_gemma":[0.9980672,0.0009915436,0.0005537999,0.00009984963,0.00017186045,0.00011572105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015956174,0.00015438163,0.0006742184,0.00010296025,0.00020919162,0.00030061693,0.00013421611,0.00034778088,0.0008632442],"category_scores_gemma":[0.0027268531,0.00010469163,0.0005523821,0.00014335538,0.0001709,0.00028777198,0.00010618983,0.00045671887,0.00018812146],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045857918,0.0025471963,0.19854711,0.0015726233,0.002138275,0.0028100084,0.0011572498,0.0021682072,0.17397268,0.00023559705,0.0017482034,0.56724507],"study_design_scores_gemma":[0.0041476646,0.163027,0.7786921,0.00017279232,0.0017071143,0.010458425,0.0004919922,0.0029735854,0.030163106,0.0004501187,0.007649063,0.00006704939],"about_ca_topic_score_codex":0.000269141,"about_ca_topic_score_gemma":0.00052348024,"teacher_disagreement_score":0.0015956174,"about_ca_system_score_codex":0.00024188135,"about_ca_system_score_gemma":0.00010327334,"threshold_uncertainty_score":0.008438528},"labels":[],"label_agreement":null},{"id":"W1977455030","doi":"10.1097/01.wnf.0000220817.94102.95","title":"The Controversy Concerning Plasma Homocysteine in Parkinson Disease Patients Treated with Levodopa Alone or with Entacapone","year":2006,"lang":"en","type":"review","venue":"Clinical Neuropharmacology","topic":"Folate and B Vitamins Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"","keywords":"Entacapone; Levodopa; Catechol-O-methyl transferase; Parkinson's disease; Homocysteine; Hyperhomocysteinemia; Concomitant; Medicine; Plasma homocysteine; Internal medicine; Pharmacology; Endocrinology; Psychology; Disease; Chemistry; Biochemistry; Genotype","score_opus":0.09628879543517495,"score_gpt":0.4267736520732911,"score_spread":0.33048485663811616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977455030","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007840191,0.9993305,0.000013463955,0.0003186052,0.00007216334,9.854381e-7,0.0000039189968,0.0000010282077,0.00018103354],"genre_scores_gemma":[0.00084419583,0.998502,0.00006434859,0.00033107316,0.00013081572,0.0000037944005,0.00000940924,5.416664e-7,0.00011378524],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995073,0.00013909586,0.00013652108,0.00007785238,0.00011736619,0.000021874079],"domain_scores_gemma":[0.9991372,0.0005153486,0.00013335065,0.00001588069,0.00016614459,0.000032021006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014761701,0.00047145336,0.0029144913,0.0018873689,0.00032027843,0.0012336927,0.0010991142,0.0017456649,0.001784382],"category_scores_gemma":[0.002467233,0.00024528528,0.00062085025,0.0024099504,0.0007230937,0.0011491965,0.00049281586,0.0013898575,0.0008813609],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003388841,0.000034529963,0.00046643737,0.040829666,0.00032252065,0.0005727937,0.00016863737,0.00007443948,0.0009557416,0.0016728427,0.019482287,0.93508124],"study_design_scores_gemma":[0.00022760243,0.00036748918,0.005022862,0.041997954,0.0017312695,0.007886352,0.00052677136,0.00006587424,0.0011070877,0.0032486126,0.93777037,0.000047767066],"about_ca_topic_score_codex":0.0014285273,"about_ca_topic_score_gemma":0.0024311084,"teacher_disagreement_score":0.0029144913,"about_ca_system_score_codex":0.0007191234,"about_ca_system_score_gemma":0.0014580584,"threshold_uncertainty_score":0.0078068376},"labels":[],"label_agreement":null},{"id":"W1980626997","doi":"10.1097/wnf.0b013e31804c780e","title":"Gambling and Increased Sexual Desire With Dopaminergic Medications in Restless Legs Syndrome","year":2007,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Restless Legs Syndrome Research","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"","keywords":"Pramipexole; Ropinirole; Restless legs syndrome; Dopaminergic; Psychology; Levodopa; Parkinson's disease; Mania; Psychiatry; Dopamine agonist; Disease; Medicine; Internal medicine; Dopamine; Bipolar disorder; Neuroscience; Neurology; Mood","score_opus":0.11062389079381042,"score_gpt":0.4626233068166211,"score_spread":0.3519994160228107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980626997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99908173,0.00032879153,0.00003846575,0.00006647851,0.0000034736577,0.00000887005,0.00006125351,0.0000014067126,0.00040953082],"genre_scores_gemma":[0.999666,0.00012894954,0.000041603573,0.000044577457,0.0000073839306,0.0000028647007,0.00005264564,2.861933e-7,0.000055630655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99956936,0.00018451549,0.00006543517,0.0000362261,0.00010136876,0.000043056334],"domain_scores_gemma":[0.99829775,0.0004968947,0.00092550955,0.000029064557,0.000096463846,0.00015424585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059912854,0.0001455014,0.00022524985,0.00052849826,0.00016816298,0.00035933458,0.00014155394,0.00033937022,0.0017096448],"category_scores_gemma":[0.0033338794,0.000121027355,0.00039520787,0.0003958149,0.0002674591,0.00035614855,0.00028676138,0.00032160943,0.00012937978],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007689484,0.00004211537,0.9967878,0.000027092718,0.000035154997,0.00019536748,0.00006748038,0.00002796521,0.00011555927,0.0000079846295,0.000047996502,0.0025686792],"study_design_scores_gemma":[0.000008757187,0.0001947654,0.9976337,0.000014183659,0.000020017815,0.0016665993,0.00015890256,0.00014790034,0.000052823776,0.000013188714,0.00008641072,0.0000027611845],"about_ca_topic_score_codex":0.0012886935,"about_ca_topic_score_gemma":0.0024053417,"teacher_disagreement_score":0.0017096448,"about_ca_system_score_codex":0.00016473055,"about_ca_system_score_gemma":0.00015056453,"threshold_uncertainty_score":0.005719304},"labels":[],"label_agreement":null},{"id":"W1980632974","doi":"10.1097/wnf.0b013e31827db49b","title":"Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease","year":2013,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Parkwood Institute","funders":"","keywords":"Medicine; Adverse effect; Pharmacokinetics; Placebo; Anesthesia; Pharmacodynamics; Cerebrospinal fluid; Gastroenterology; Internal medicine; Pathology","score_opus":0.05818489725870915,"score_gpt":0.3828051632185218,"score_spread":0.32462026595981264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980632974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984884,0.00063495897,0.00021197791,0.0000510224,0.000024613952,0.00020524021,0.0000683713,0.000035773184,0.00027965798],"genre_scores_gemma":[0.99862397,0.00025683825,0.00033628938,0.00007301748,0.000047927424,0.00016926407,0.000093915136,0.0000045954607,0.000394191],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99970895,0.00011219048,0.000015693817,0.0000678393,0.000045598954,0.000049600258],"domain_scores_gemma":[0.9995658,0.00009984213,0.00013297495,0.000041485222,0.000038257513,0.00012162421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006363704,0.00069448346,0.0013030259,0.00019891001,0.00027854912,0.0004307026,0.00043617366,0.00086903985,0.0018368416],"category_scores_gemma":[0.0010128808,0.000285905,0.00043343456,0.00013009706,0.0004648713,0.00048798783,0.00016022314,0.0012368561,0.00046502106],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60452133,0.04186816,0.010330142,0.00071166083,0.00072457606,0.0003486275,0.00023321788,0.0011534157,0.16178012,0.00008494601,0.001028003,0.17721575],"study_design_scores_gemma":[0.14045084,0.7947584,0.045742042,0.000034772307,0.0004136501,0.00057761004,0.000059442275,0.0013862093,0.015101389,0.000083511855,0.0013616487,0.00003061443],"about_ca_topic_score_codex":0.00042157708,"about_ca_topic_score_gemma":0.00078675227,"teacher_disagreement_score":0.0018368416,"about_ca_system_score_codex":0.00036724418,"about_ca_system_score_gemma":0.00052474614,"threshold_uncertainty_score":0.0061448216},"labels":[],"label_agreement":null},{"id":"W1980849388","doi":"10.1097/01.wnf.0000174932.82134.e2","title":"Quetiapine for Insomnia in Parkinson Disease","year":2005,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Restless Legs Syndrome Research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"","keywords":"Quetiapine; Pittsburgh Sleep Quality Index; Epworth Sleepiness Scale; Insomnia; Internal medicine; Medicine; Excessive daytime sleepiness; Rating scale; Polysomnography; Hypnotic; Psychology; Anesthesia; Sleep disorder; Psychiatry; Schizophrenia (object-oriented programming); Sleep quality","score_opus":0.1265459834756793,"score_gpt":0.5002710878749101,"score_spread":0.37372510439923085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980849388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97012997,0.02557955,0.00054425915,0.00030556822,0.00014378956,0.00026834698,0.00018843745,0.00009264478,0.0027475085],"genre_scores_gemma":[0.9857488,0.010799864,0.0007689786,0.00041048502,0.00021457182,0.00013737522,0.00038910727,0.00001100504,0.0015198974],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99984956,0.00006654808,0.000015373407,0.000014830766,0.00003056991,0.000023112336],"domain_scores_gemma":[0.999764,0.000075639204,0.00005059121,0.000010377598,0.000016127786,0.000083324616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038524522,0.00032566488,0.00085842196,0.0001988649,0.00022790873,0.00024391935,0.000314218,0.00044866107,0.0012698089],"category_scores_gemma":[0.0006535794,0.000078928824,0.0004684553,0.00020944809,0.00021689803,0.0001687274,0.0001030519,0.0005469465,0.00025151655],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21512075,0.009132589,0.024768906,0.002569891,0.0012361567,0.00223381,0.00025585966,0.00072801206,0.0856372,0.0004059749,0.0052990457,0.6526118],"study_design_scores_gemma":[0.24058567,0.32393858,0.37230724,0.0004544575,0.0019468166,0.008360346,0.00021468382,0.0039874488,0.01949566,0.0007882227,0.027838906,0.0000819027],"about_ca_topic_score_codex":0.0011402186,"about_ca_topic_score_gemma":0.0035979557,"teacher_disagreement_score":0.0012698089,"about_ca_system_score_codex":0.00028288102,"about_ca_system_score_gemma":0.00031171198,"threshold_uncertainty_score":0.0042479634},"labels":[],"label_agreement":null},{"id":"W1986554664","doi":"10.1097/00002826-200107000-00010","title":"Amoxapine Shows an Antipsychotic Effect but Worsens Motor Function in Patients with Parkinson's Disease and Psychosis","year":2001,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"","keywords":"Antipsychotic; Psychosis; Medicine; Parkinson's disease; Concomitant; Disease; Motor function; Antidepressant; Schizophrenia (object-oriented programming); Psychiatry; Antipsychotic drug; Internal medicine; Physical medicine and rehabilitation","score_opus":0.029953791314842437,"score_gpt":0.3633971418893481,"score_spread":0.33344335057450564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986554664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99567187,0.001689124,0.000096399126,0.00026914533,0.00002228368,0.00001894681,0.00003823753,0.000013375291,0.0021806813],"genre_scores_gemma":[0.9990835,0.00040204104,0.000119063465,0.00013723635,0.000020376274,0.0000048959896,0.000048041664,0.0000017011307,0.0001831858],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99958414,0.00011760132,0.0000847103,0.000039696064,0.0001120518,0.00006188071],"domain_scores_gemma":[0.9991185,0.00024491418,0.00027385252,0.000029533147,0.00008640251,0.00024685956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058948377,0.0004891344,0.00071963726,0.0003996388,0.0005393981,0.0005378464,0.00015489077,0.0007086782,0.0010279749],"category_scores_gemma":[0.0024954693,0.00029681812,0.00041320422,0.00033798476,0.0003134377,0.00043343432,0.00026688544,0.0005216062,0.00019893392],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016550088,0.0012894798,0.79892266,0.0007679298,0.0005996915,0.034872346,0.0012358215,0.0007207109,0.05165434,0.00044609938,0.0013254145,0.091615446],"study_design_scores_gemma":[0.0008477062,0.0071492037,0.95137054,0.00008645943,0.00030226528,0.03354136,0.00041580785,0.0007485791,0.0031551875,0.00040482203,0.0019270964,0.000050992432],"about_ca_topic_score_codex":0.0019624878,"about_ca_topic_score_gemma":0.005269291,"teacher_disagreement_score":0.0019624878,"about_ca_system_score_codex":0.00042779185,"about_ca_system_score_gemma":0.00032812316,"threshold_uncertainty_score":0.0039021373},"labels":[],"label_agreement":null},{"id":"W1987370838","doi":"10.1097/wnf.0b013e31815cba61","title":"Variability of the In Vivo Metabolism of Clozapine","year":2008,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Defense Medical College","keywords":"Clozapine; Metabolite; In vivo; Schizophrenia (object-oriented programming); Pharmacology; Antipsychotic; Atypical antipsychotic; Metabolism; Psychology; Chemistry; Endocrinology; Internal medicine; Medicine; Biology; Psychiatry","score_opus":0.07665838262348112,"score_gpt":0.4100766655505208,"score_spread":0.3334182829270397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987370838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931558,0.00096521236,0.004344388,0.000032083663,0.000019465218,0.000033207907,0.0005167853,0.00006781878,0.0008652785],"genre_scores_gemma":[0.99832517,0.00012571766,0.00076220004,0.000023417451,0.000011984029,0.000019157147,0.0005197307,0.000013614333,0.0001989045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844885,0.00064215116,0.00014103173,0.00040018297,0.0003145636,0.00005311416],"domain_scores_gemma":[0.99791163,0.0009647134,0.0004208799,0.00041768225,0.00023147037,0.000053518677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009415461,0.00028734186,0.0003979662,0.0003098173,0.00018529216,0.00058927614,0.00019384224,0.00035590076,0.0007847198],"category_scores_gemma":[0.0030356278,0.00018230922,0.00020283122,0.0003238555,0.00028778324,0.00014929746,0.00019930452,0.00031769287,0.00029824208],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008686177,0.00034080303,0.60767967,0.0002836162,0.0019224439,0.00038574464,0.0008542699,0.00245993,0.32221726,0.00025575847,0.00071595283,0.054198343],"study_design_scores_gemma":[0.00007138122,0.0011529505,0.9386,0.000013443327,0.0002651479,0.0015498748,0.00010940032,0.00311389,0.05322242,0.00017032695,0.0017029733,0.000028086843],"about_ca_topic_score_codex":0.0012845772,"about_ca_topic_score_gemma":0.0010594623,"teacher_disagreement_score":0.0012845772,"about_ca_system_score_codex":0.0002428498,"about_ca_system_score_gemma":0.0001131092,"threshold_uncertainty_score":0.0049794316},"labels":[],"label_agreement":null},{"id":"W1993332355","doi":"10.1097/00002826-200401000-00008","title":"Effect of Riluzole on Dyskinesia and Duration of the ON State in Parkinson Disease Patients","year":2004,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"","keywords":"Riluzole; Dyskinesia; Placebo; Levodopa; Apomorphine; Parkinson's disease; Anesthesia; Medicine; Psychology; Amyotrophic lateral sclerosis; Internal medicine; Disease; Dopaminergic; Dopamine","score_opus":0.016343561423508103,"score_gpt":0.3469000184184506,"score_spread":0.33055645699494246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993332355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958217,0.0029562716,0.000053683514,0.00004237257,0.000015713777,0.000026526346,0.00005005405,0.000008178684,0.0010255208],"genre_scores_gemma":[0.99836475,0.00086341077,0.00016567625,0.0000903433,0.00003358414,0.000021101128,0.00014919887,0.0000023553673,0.00030949828],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997683,0.00011434381,0.000030639163,0.000021533058,0.00003406955,0.000031086718],"domain_scores_gemma":[0.9995029,0.00017580487,0.00012326142,0.000025846857,0.000049404,0.00012266875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000365616,0.00037838693,0.00085908105,0.00017127716,0.00016149822,0.00026702086,0.00016468923,0.00031275145,0.0007994461],"category_scores_gemma":[0.0010460304,0.000099304314,0.00042192827,0.0001249411,0.00014671206,0.00019819687,0.00012711938,0.00037827098,0.00014387631],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19285436,0.009535142,0.214745,0.001224058,0.0024418985,0.0013699796,0.0005840309,0.0007610521,0.15497705,0.00013846123,0.0011741143,0.4201948],"study_design_scores_gemma":[0.009691263,0.17392372,0.79680693,0.00009613845,0.0012519037,0.0018356853,0.00028255154,0.0010442241,0.011588331,0.00008368864,0.0033518437,0.000043709442],"about_ca_topic_score_codex":0.00047666012,"about_ca_topic_score_gemma":0.0015303966,"teacher_disagreement_score":0.00085908105,"about_ca_system_score_codex":0.00019443234,"about_ca_system_score_gemma":0.00012435514,"threshold_uncertainty_score":0.0026744008},"labels":[],"label_agreement":null},{"id":"W2002651101","doi":"10.1097/wnf.0b013e318263163c","title":"Immunogenicity and Long-Term Efficacy of Botulinum Toxin Type B in the Treatment of Cervical Dystonia","year":2012,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cervical dystonia; Immunogenicity; Medicine; Botulinum toxin; Seroconversion; Adverse effect; Internal medicine; Clinical trial; Botulism; Spasmodic Torticollis; Antibody; Immunology; Surgery; Torticollis; Biology","score_opus":0.07284874114159376,"score_gpt":0.4068194709946589,"score_spread":0.3339707298530652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002651101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852341,0.01358558,0.00024270044,0.00011057313,0.0000243266,0.00006182276,0.00006402498,0.0000059901895,0.0006708695],"genre_scores_gemma":[0.99824476,0.0012927611,0.000107854685,0.000056910216,0.00003716369,0.000027750031,0.00008074823,0.0000014877899,0.00015068286],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981787,0.00085140736,0.00028198678,0.00012422437,0.00046794282,0.00009562857],"domain_scores_gemma":[0.9953015,0.0016995898,0.0020783383,0.00020773576,0.00048178466,0.0002309755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0063911695,0.00021666074,0.000409725,0.00022376556,0.00022004085,0.0003942013,0.00026531832,0.00047027136,0.0006420717],"category_scores_gemma":[0.0047478806,0.00013926429,0.0007209376,0.00021244875,0.00033523858,0.00048525527,0.0002573176,0.000491474,0.00012790448],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1446569,0.01620849,0.3044552,0.0047302227,0.008541466,0.0008102628,0.0009337,0.0038481737,0.11354436,0.00032512314,0.0010467794,0.40089947],"study_design_scores_gemma":[0.00481099,0.2798256,0.6820362,0.0004592901,0.0031208145,0.0016060794,0.00018723405,0.001658593,0.023098204,0.00013773252,0.0030215436,0.000037757425],"about_ca_topic_score_codex":0.00036181128,"about_ca_topic_score_gemma":0.00040284314,"teacher_disagreement_score":0.0063911695,"about_ca_system_score_codex":0.00037900376,"about_ca_system_score_gemma":0.00030951967,"threshold_uncertainty_score":0.033800125},"labels":[],"label_agreement":null},{"id":"W2005346374","doi":"10.1097/00002826-200007000-00003","title":"Mexiletine in the Treatment of Torticollis and Generalized Dystonia","year":2000,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Spasmodic Torticollis; Mexiletine; Dystonia; Medicine; Anesthesia; Torticollis; Rating scale; Trihexyphenidyl; Adverse effect; Psychology; Internal medicine; Surgery; Psychiatry","score_opus":0.052729010682651935,"score_gpt":0.395296412991609,"score_spread":0.34256740230895705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005346374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854253,0.011788389,0.00035452392,0.00017325321,0.00002455412,0.000067421686,0.000038503633,0.000033284192,0.0020947382],"genre_scores_gemma":[0.99568486,0.0032660277,0.00041291164,0.00010645048,0.000041586587,0.000022888846,0.00007180852,0.0000032980483,0.00039015544],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99988854,0.000056893736,0.000011972525,0.000010644054,0.00001640167,0.000015532833],"domain_scores_gemma":[0.99983966,0.000056811685,0.000044336648,0.0000102103995,0.0000086047285,0.00004040094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023390153,0.00026331889,0.0005302239,0.00016199978,0.00014837131,0.000090093854,0.00016068688,0.0002196363,0.0008888176],"category_scores_gemma":[0.0005173876,0.000060687682,0.00022926241,0.00015214164,0.00017382303,0.00010488149,0.00014930642,0.0003744972,0.00009339372],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027333783,0.0029917362,0.027877701,0.0023686723,0.0006539082,0.011402838,0.0006940711,0.001881768,0.19699115,0.00039959612,0.0022230917,0.72518164],"study_design_scores_gemma":[0.021165099,0.21160932,0.6852356,0.00033296476,0.000822501,0.028231854,0.0003669955,0.0035018637,0.02718294,0.00037509672,0.021081705,0.00009403407],"about_ca_topic_score_codex":0.0011546055,"about_ca_topic_score_gemma":0.0036188166,"teacher_disagreement_score":0.0011546055,"about_ca_system_score_codex":0.00017292406,"about_ca_system_score_gemma":0.0001726848,"threshold_uncertainty_score":0.0029734373},"labels":[],"label_agreement":null},{"id":"W2007751663","doi":"10.1097/wnf.0000000000000016","title":"Cannabis (Medical Marijuana) Treatment for Motor and Non–Motor Symptoms of Parkinson Disease","year":2014,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":214,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cannabis; Medicine; Rating scale; McGill Pain Questionnaire; Parkinson's disease; Disease; Observational study; Physical therapy; Visual analogue scale; Psychiatry; Psychology; Internal medicine","score_opus":0.031976687118068566,"score_gpt":0.3959902137891548,"score_spread":0.3640135266710862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007751663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98950446,0.008723335,0.000080411075,0.00015010664,0.000022870365,0.00008394923,0.000099839555,0.000009531169,0.0013255067],"genre_scores_gemma":[0.9968117,0.002440163,0.00017847038,0.00006901472,0.000026254882,0.000023876702,0.000063393825,9.583873e-7,0.00038618926],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9998029,0.000069682676,0.000023700606,0.00002052823,0.000052466487,0.00003081799],"domain_scores_gemma":[0.9997638,0.000053718988,0.00009902347,0.000008869819,0.000023189436,0.000051330484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020394979,0.0001416994,0.00039613992,0.00022667999,0.00039567062,0.00016602184,0.00016258223,0.00023998939,0.0017526194],"category_scores_gemma":[0.0006300311,0.00007216668,0.00026324284,0.00021076183,0.00017950007,0.00011970582,0.00015417025,0.0002860768,0.00019987677],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03137215,0.012566315,0.41725987,0.0035609275,0.0011788254,0.0031905356,0.00090235064,0.00045206342,0.057536405,0.00026337424,0.0026570347,0.46906006],"study_design_scores_gemma":[0.0016441387,0.02141351,0.9641481,0.00019778805,0.00024512026,0.003595493,0.0003176569,0.00050112704,0.0034630569,0.0001185445,0.0043325094,0.00002295838],"about_ca_topic_score_codex":0.0015878046,"about_ca_topic_score_gemma":0.0067478595,"teacher_disagreement_score":0.0017526194,"about_ca_system_score_codex":0.000255942,"about_ca_system_score_gemma":0.00034004613,"threshold_uncertainty_score":0.0058630705},"labels":[],"label_agreement":null},{"id":"W2018391979","doi":"10.1097/00002826-200007000-00005","title":"Sustained Cabergoline Treatment Reverses Levodopa-Induced Dyskinesias in Parkinsonian Monkeys","year":2000,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Cabergoline; Benserazide; Dyskinesia; Levodopa; Dopamine; Medicine; Parkinson's disease; MPTP; Decarboxylase inhibitor; Dopamine agonist; Agonist; Dopamine receptor D2; Internal medicine; Anesthesia; Pharmacology; Endocrinology; Receptor; Dopaminergic; Disease; Prolactin","score_opus":0.06180993642833334,"score_gpt":0.3893135241711484,"score_spread":0.32750358774281507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018391979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987519,0.00060711475,0.00014471025,0.000029616525,0.000010939164,0.000015718946,0.00006456868,0.000035288755,0.00034011697],"genre_scores_gemma":[0.99728715,0.00057620724,0.0005160977,0.00004407626,0.00001797406,0.000048551305,0.0002918659,0.000019439392,0.0011987806],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99987566,0.000020877615,0.0000123172995,0.000020049067,0.000018464412,0.000052636748],"domain_scores_gemma":[0.99981683,0.000022831258,0.000052612224,0.000021178828,0.000020570256,0.00006605669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000109535635,0.00039789357,0.0004998575,0.00033477513,0.00024458888,0.00030790592,0.0002407163,0.00042234702,0.0004341901],"category_scores_gemma":[0.00017813045,0.00016957414,0.00023051948,0.00010215227,0.0002564249,0.0001761064,0.00014274172,0.00060984265,0.00025601618],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006122668,0.00019355441,0.0005182295,0.000035091944,0.000011215748,0.00011514207,0.000043149004,0.000041696087,0.9961259,0.000020254474,0.000033974637,0.0022495904],"study_design_scores_gemma":[0.00045318264,0.016788306,0.03749119,0.000033253826,0.00013105068,0.0008935989,0.00015947185,0.0017687167,0.93881094,0.00009559914,0.0033558747,0.000018864717],"about_ca_topic_score_codex":0.0016764826,"about_ca_topic_score_gemma":0.0038549001,"teacher_disagreement_score":0.0016764826,"about_ca_system_score_codex":0.00038909557,"about_ca_system_score_gemma":0.0002445173,"threshold_uncertainty_score":0.003333509},"labels":[],"label_agreement":null},{"id":"W2018810282","doi":"10.1097/00002826-200105000-00005","title":"Double-blind, Crossover, Placebo-controlled Trial of Bromocriptine in Patients with Sleep Bruxism","year":2001,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Temporomandibular Joint Disorders","field":"Health Professions","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Bromocriptine; Placebo; Crossover study; Medicine; Sleep Bruxism; Anesthesia; Internal medicine; Electromyography; Hormone; Prolactin; Physical medicine and rehabilitation","score_opus":0.08322264891113389,"score_gpt":0.46124257906078703,"score_spread":0.3780199301496531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018810282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825759,0.007547473,0.0010015626,0.0006186425,0.0009897784,0.004312125,0.0006715768,0.00023114668,0.0020518603],"genre_scores_gemma":[0.9840836,0.0028371403,0.0019418903,0.0011231486,0.00093491084,0.006148176,0.0006890504,0.000026348913,0.002215749],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992368,0.0003514681,0.00007868901,0.00015722748,0.00006513191,0.000110553316],"domain_scores_gemma":[0.99900645,0.00032709856,0.0001476289,0.00009038784,0.00009064802,0.00033783008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013296449,0.0015207538,0.005071274,0.0005697186,0.00061245187,0.00080836314,0.00085564627,0.0024185565,0.0051705902],"category_scores_gemma":[0.0020081087,0.00074680825,0.0010678656,0.00043584887,0.0012365698,0.0009164385,0.0003463571,0.0020319645,0.0009424441],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96641326,0.008492027,0.0005649586,0.00057551236,0.000477603,0.00005216879,0.000058505,0.00014637713,0.004951485,0.000059299735,0.00046723947,0.017741596],"study_design_scores_gemma":[0.9121834,0.08463429,0.0019367918,0.000014534856,0.0001551738,0.00002358178,0.000015524789,0.00016703809,0.000344638,0.000044343586,0.00047071002,0.000009998429],"about_ca_topic_score_codex":0.00055889983,"about_ca_topic_score_gemma":0.0010573358,"teacher_disagreement_score":0.0051705902,"about_ca_system_score_codex":0.00043377493,"about_ca_system_score_gemma":0.0008651979,"threshold_uncertainty_score":0.017297328},"labels":[],"label_agreement":null},{"id":"W2025416757","doi":"10.1097/00002826-200109000-00002","title":"Acute Spinal Cord Injury, Part I: Pathophysiologic Mechanisms","year":2001,"lang":"en","type":"review","venue":"Clinical Neuropharmacology","topic":"Spinal Cord Injury Research","field":"Medicine","cited_by":730,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia","funders":"","keywords":"Medicine; Spinal cord injury; Excitotoxicity; Neuroprotection; Pathophysiology; Neuroscience; Ischemia; Intensive care medicine; Spinal cord; Pathology; Internal medicine; Psychology; Psychiatry; Glutamate receptor","score_opus":0.32552044224916427,"score_gpt":0.587321250806737,"score_spread":0.26180080855757276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025416757","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018588448,0.9977075,0.00026088045,0.00028867938,0.00019654032,0.0000129752125,0.000010565979,0.000009527541,0.0013275269],"genre_scores_gemma":[0.0009253027,0.99763644,0.00022048666,0.00015333346,0.00031227717,0.000014992163,0.000016363432,9.799181e-7,0.00071976],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997427,0.00004929423,0.000048601596,0.000050053743,0.00008879614,0.000020502986],"domain_scores_gemma":[0.9997509,0.000092969705,0.00004570379,0.000010124788,0.000077165285,0.000023190596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000441469,0.0014917993,0.0016605234,0.0015070954,0.00041138372,0.001390111,0.0009885319,0.0017201492,0.0031226687],"category_scores_gemma":[0.00046132432,0.00029163965,0.00039953308,0.0020797749,0.00123182,0.0018228802,0.0005414315,0.0014650668,0.0029739337],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009272496,0.00025476018,0.00066203147,0.020762337,0.000051705767,0.00067620416,0.00018235283,0.00043185047,0.008595185,0.005248685,0.026646327,0.93639576],"study_design_scores_gemma":[0.000042900912,0.00061981054,0.006801613,0.006675585,0.00013253007,0.010170896,0.00037191136,0.00020977792,0.0027962856,0.011580388,0.9605544,0.00004392456],"about_ca_topic_score_codex":0.0010762654,"about_ca_topic_score_gemma":0.0011301452,"teacher_disagreement_score":0.0031226687,"about_ca_system_score_codex":0.0008134589,"about_ca_system_score_gemma":0.0013909189,"threshold_uncertainty_score":0.01044631},"labels":[],"label_agreement":null},{"id":"W2028210993","doi":"10.1097/wnf.0b013e3181ac155b","title":"Milnacipran","year":2009,"lang":"en","type":"review","venue":"Clinical Neuropharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McGill University","keywords":"Milnacipran; Fibromyalgia; Antidepressant; Reuptake inhibitor; Pharmacology; Venlafaxine; Duloxetine; Tolerability; Psychology; Medicine; Internal medicine; Psychiatry; Anxiety; Adverse effect","score_opus":0.29603911199501876,"score_gpt":0.5823993394174389,"score_spread":0.2863602274224202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028210993","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006892118,0.9927625,0.000335499,0.00023212303,0.00027644853,0.00003125999,0.00007231894,0.000046988465,0.0055536972],"genre_scores_gemma":[0.004922305,0.9879048,0.0008019618,0.0006451261,0.00022590664,0.000046700436,0.00026841764,0.0000063797384,0.0051783314],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998572,0.000025769761,0.000021309064,0.00002721175,0.00005440381,0.000014173984],"domain_scores_gemma":[0.9999286,0.000022040382,0.000020646754,0.0000030912577,0.000015303718,0.000010366911],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018011712,0.00085947895,0.0009896636,0.0016264553,0.00021768696,0.00058307254,0.0007347065,0.0006945927,0.006386014],"category_scores_gemma":[0.0003204938,0.00018755299,0.00038404524,0.0011590812,0.00018937276,0.00066730427,0.00052513694,0.0011585184,0.004209433],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017561828,0.000094105926,0.000090522706,0.0099043865,0.00008778867,0.00023150088,0.000034527508,0.00013254517,0.0031065028,0.0010953213,0.019785805,0.9652613],"study_design_scores_gemma":[0.000113314636,0.00020693646,0.0012302353,0.0022986901,0.00013118454,0.0024759439,0.000029519044,0.00009922001,0.002296525,0.0008398762,0.9902596,0.000019005745],"about_ca_topic_score_codex":0.0006291017,"about_ca_topic_score_gemma":0.0012650051,"teacher_disagreement_score":0.006386014,"about_ca_system_score_codex":0.00029927687,"about_ca_system_score_gemma":0.00039617505,"threshold_uncertainty_score":0.021363318},"labels":[],"label_agreement":null},{"id":"W2028615441","doi":"10.1097/wnf.0000000000000020","title":"Generalized Myoclonus and Spasticity Induced by Lamotrigine Toxicity","year":2014,"lang":"en","type":"review","venue":"Clinical Neuropharmacology","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Myoclonus; Lamotrigine; Status epilepticus; Medicine; Anesthesia; Anticonvulsant; Myoclonic Jerk; Epilepsy; Convulsion; Toxicity; Internal medicine; Psychiatry","score_opus":0.15092536508325527,"score_gpt":0.49634606446188906,"score_spread":0.3454206993786338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028615441","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00072288944,0.9971105,0.000116148316,0.0002017998,0.00006442883,0.000008054268,0.00002584082,0.0000134400925,0.0017367952],"genre_scores_gemma":[0.005239412,0.99359244,0.0001279381,0.0002110552,0.00012343517,0.000008904596,0.000043905013,0.0000022678164,0.0006506558],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998306,0.000028807639,0.00003678037,0.000030957646,0.00005087191,0.00002185446],"domain_scores_gemma":[0.99981564,0.00006517045,0.000059397873,0.000007175415,0.000037638998,0.000015033969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023655426,0.0008178362,0.0010941264,0.002537209,0.00024988115,0.0006369517,0.00061630626,0.0007423066,0.0027195003],"category_scores_gemma":[0.00046945666,0.00016727127,0.00062953116,0.0022368205,0.0004092794,0.00056469406,0.0004797234,0.00080605515,0.0011117492],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000088259185,0.00007061212,0.0011097142,0.028700536,0.00024365839,0.0050471695,0.000113573384,0.00032423934,0.0031078833,0.0016249806,0.022955434,0.936614],"study_design_scores_gemma":[0.00010002273,0.00021838308,0.012147919,0.011887728,0.00066021836,0.09763611,0.0002990553,0.00025430694,0.0028996344,0.003206549,0.87063694,0.00005319335],"about_ca_topic_score_codex":0.0016195264,"about_ca_topic_score_gemma":0.00324363,"teacher_disagreement_score":0.0027195003,"about_ca_system_score_codex":0.00049495295,"about_ca_system_score_gemma":0.0009086944,"threshold_uncertainty_score":0.009097636},"labels":[],"label_agreement":null},{"id":"W2032203345","doi":"10.1097/wnf.0b013e3181f8d4ed","title":"Evidence for Use of Mood Stabilizers and Anticonvulsants in the Treatment of Nonaffective Disorders in Children and Adolescents","year":2010,"lang":"en","type":"review","venue":"Clinical Neuropharmacology","topic":"Child and Adolescent Psychosocial and Emotional Development","field":"Psychology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Hotel Dieu Hospital","funders":"","keywords":"Mood; Mood disorders; Lithium (medication); Psychiatry; Mood stabilizer; Divalproex; Anticonvulsant; Psychology; Bipolar disorder; Lamotrigine; Clinical psychology; Medicine; Mania; Anxiety; Epilepsy","score_opus":0.17072241895368406,"score_gpt":0.4752191105979739,"score_spread":0.30449669164428983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032203345","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016715098,0.9995122,0.000010380625,0.0000654071,0.00002002195,0.0000023087389,0.000008535686,8.1404403e-7,0.00021316476],"genre_scores_gemma":[0.0016481094,0.99812156,0.00008034646,0.00007342244,0.000021248636,0.0000037691161,0.000010628489,4.6555002e-7,0.000040433224],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99910694,0.00025529927,0.00027049248,0.00009291585,0.0002404113,0.000033868633],"domain_scores_gemma":[0.99710494,0.0019471091,0.0006000456,0.000034782017,0.00025904056,0.00005413126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001817232,0.0005494763,0.0017732735,0.0028503148,0.00019923935,0.00094625936,0.00085946673,0.0009410367,0.0033925422],"category_scores_gemma":[0.0038980502,0.00031433065,0.0011979076,0.0031691997,0.00044767204,0.0006049555,0.00045848746,0.00081921206,0.0005000591],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027310284,0.000075847536,0.0020752857,0.19467548,0.0013615038,0.00061043864,0.00016335577,0.00013960585,0.0009247818,0.000899281,0.006411326,0.79239],"study_design_scores_gemma":[0.00038108797,0.0008645861,0.0376592,0.4043958,0.012211901,0.011351921,0.0007906274,0.0001427263,0.0019687293,0.001529165,0.5286448,0.00005944562],"about_ca_topic_score_codex":0.0024424943,"about_ca_topic_score_gemma":0.0054471768,"teacher_disagreement_score":0.0033925422,"about_ca_system_score_codex":0.0006025422,"about_ca_system_score_gemma":0.0020398924,"threshold_uncertainty_score":0.011349201},"labels":[],"label_agreement":null},{"id":"W2032852860","doi":"10.1097/00002826-200207000-00005","title":"Cognitive Deficits and Striatal Dopaminergic Denervation in Parkinson's Disease: A Single Photon Emission Computed Tomography Study Using 123Iodine-β-CIT in Patients ON and OFF Levodopa","year":2002,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal; Centre Hospitalier de l’Université de Montréal; Ottawa Hospital","funders":"","keywords":"Dopaminergic; Parkinson's disease; Levodopa; Cognition; Denervation; Psychology; Neuroscience; Executive functions; Single-photon emission computed tomography; Audiology; Medicine; Internal medicine; Disease; Dopamine","score_opus":0.0769197879628581,"score_gpt":0.34601148228322126,"score_spread":0.2690916943203632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032852860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99970067,0.00006607138,0.00001662653,0.00000605393,0.0000013639925,0.000005291704,0.00003534024,0.0000012959423,0.0001674504],"genre_scores_gemma":[0.9995814,0.00006448994,0.000048044156,0.000020216132,0.000005816723,0.000007027712,0.00011172721,9.0073087e-7,0.00016033226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998934,0.000013703535,0.0000166571,0.00002783985,0.000024202725,0.000024192339],"domain_scores_gemma":[0.9995492,0.00010539023,0.00009438897,0.000024024204,0.00005116426,0.00017586183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001761341,0.00068061275,0.00063806237,0.0009622423,0.0007241626,0.0004045343,0.0002537148,0.00082893064,0.0012330366],"category_scores_gemma":[0.0007859943,0.00040947826,0.00045027822,0.00057530386,0.00056014134,0.00033441215,0.00031580884,0.00058716984,0.00020751139],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004553098,0.0012136756,0.9685421,0.00005674823,0.00016780867,0.008912056,0.0008439768,0.00017699583,0.010476986,0.000034288067,0.00009629697,0.004925907],"study_design_scores_gemma":[0.00006651712,0.001961897,0.99104285,0.000004246174,0.000055653774,0.0058707735,0.00025846247,0.00018767912,0.00041451803,0.00002401491,0.0001038275,0.000009474942],"about_ca_topic_score_codex":0.0057799206,"about_ca_topic_score_gemma":0.006053478,"teacher_disagreement_score":0.0057799206,"about_ca_system_score_codex":0.00038537194,"about_ca_system_score_gemma":0.0002645938,"threshold_uncertainty_score":0.01149255},"labels":[],"label_agreement":null},{"id":"W2033461129","doi":"10.1097/00002826-200309000-00006","title":"Lamotrigine Treatment for Post-Stroke Pathological Laughing and Crying","year":2003,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Infant Health and Development","field":"Health Professions","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre","funders":"","keywords":"Lamotrigine; Crying; Stroke (engine); Medicine; Mood; Pathological; Anesthesia; Serotonin reuptake inhibitor; Epilepsy; Psychology; Pediatrics; Antidepressant; Psychiatry; Internal medicine","score_opus":0.21654628396358494,"score_gpt":0.5531428008630249,"score_spread":0.33659651689944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033461129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9506998,0.029600287,0.0019261872,0.0051600384,0.00028857996,0.00018955341,0.000095623815,0.0003520329,0.011687997],"genre_scores_gemma":[0.9878405,0.008185682,0.00081746536,0.000893218,0.00018791844,0.000056813085,0.00010577572,0.00001241039,0.0019001983],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99988973,0.000032576216,0.000012714569,0.0000066867533,0.000017519638,0.000040680567],"domain_scores_gemma":[0.99987066,0.000035409812,0.00003026683,0.000008195844,0.000014804033,0.000040712937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015193563,0.0002824668,0.0004690563,0.00034655115,0.0005657805,0.000104398925,0.0002629877,0.0006734286,0.0014970909],"category_scores_gemma":[0.000847956,0.00008774866,0.0003301911,0.00019994138,0.00021441068,0.00012983284,0.00019821386,0.00060857774,0.0003764774],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071010552,0.0021078303,0.026875746,0.0019636468,0.00031339796,0.14965408,0.0011646823,0.0005601057,0.086348265,0.000981091,0.016541835,0.70638835],"study_design_scores_gemma":[0.006160478,0.02769315,0.35825616,0.00072757865,0.00081702194,0.43387973,0.001512273,0.0030744474,0.07163297,0.00215294,0.09399928,0.00009390785],"about_ca_topic_score_codex":0.0014737148,"about_ca_topic_score_gemma":0.0052865623,"teacher_disagreement_score":0.0014970909,"about_ca_system_score_codex":0.00047040448,"about_ca_system_score_gemma":0.00039999402,"threshold_uncertainty_score":0.0050082803},"labels":[],"label_agreement":null},{"id":"W2039313127","doi":"10.1097/00002826-200203000-00010","title":"Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease With Modafinil","year":2002,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Epworth Sleepiness Scale; Modafinil; Parkinson's disease; Dopamine agonist; Dopaminergic; Excessive daytime sleepiness; Medicine; Levodopa; Psychology; Internal medicine; Anesthesia; Dopamine; Disease; Psychiatry; Sleep disorder; Polysomnography; Insomnia","score_opus":0.03507027948667208,"score_gpt":0.318900012094994,"score_spread":0.28382973260832195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039313127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952296,0.0033669893,0.00014921908,0.00014090855,0.00004102245,0.00013359541,0.00005734727,0.000018004845,0.0008633984],"genre_scores_gemma":[0.99690264,0.0015555173,0.0005327342,0.00035087886,0.00011293659,0.00012568863,0.00016470977,0.0000030490728,0.00025178457],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99981505,0.000060367867,0.000035515153,0.000022597313,0.000031650583,0.00003483902],"domain_scores_gemma":[0.9995943,0.00012325682,0.000102449296,0.000019856592,0.000022278915,0.00013788676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056767324,0.00044372724,0.0011575398,0.00023553926,0.00044093357,0.0002907928,0.000288798,0.00046496702,0.000818277],"category_scores_gemma":[0.0010888812,0.00016489901,0.0004575134,0.00023409788,0.00031021453,0.0002753639,0.00018402304,0.0005837646,0.0001648968],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12610997,0.014181138,0.35829788,0.0018849863,0.0013368129,0.0059334943,0.0009257403,0.0011514572,0.08391198,0.00027102322,0.004805894,0.40118966],"study_design_scores_gemma":[0.030958228,0.13601695,0.8118622,0.00014913527,0.00040738028,0.0076069436,0.00031693542,0.0018694171,0.0036875466,0.00027161743,0.0068042274,0.000049370476],"about_ca_topic_score_codex":0.00058207556,"about_ca_topic_score_gemma":0.0022510062,"teacher_disagreement_score":0.0011575398,"about_ca_system_score_codex":0.0002756489,"about_ca_system_score_gemma":0.00029401155,"threshold_uncertainty_score":0.0030021667},"labels":[],"label_agreement":null},{"id":"W2039473736","doi":"10.1097/00002826-200403000-00009","title":"Antidepressants in the Treatment of Psychosis With Comorbid Depression in Parkinson Disease","year":2004,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Psychosis; Psychiatry; Comorbidity; Depression (economics); Exacerbation; Parkinson's disease; Psychotic depression; Antidepressant; Disease; Depressive symptoms; Medicine; Psychology; Anxiety; Internal medicine","score_opus":0.056266048015690004,"score_gpt":0.39558118217732324,"score_spread":0.3393151341616332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039473736","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42757455,0.52873075,0.0024058998,0.013206779,0.0009301969,0.0001614748,0.00009965931,0.000119840406,0.026770871],"genre_scores_gemma":[0.8886559,0.10393459,0.0024293894,0.0024424416,0.00073346205,0.000045486282,0.000057830784,0.000005160185,0.0016955747],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.999686,0.00014702504,0.00005472542,0.00001591225,0.00006416736,0.000032253436],"domain_scores_gemma":[0.99967456,0.00012693729,0.00011652509,0.000009912532,0.000023394488,0.000048647715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005222477,0.00021671735,0.00043641718,0.00041254083,0.00034545123,0.00037120597,0.00026622394,0.0012370505,0.0006972177],"category_scores_gemma":[0.0009044994,0.00016795979,0.00035040517,0.00029206008,0.0002828117,0.00023798083,0.00031615616,0.0007101876,0.00020216627],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034623132,0.0008385078,0.0569888,0.004699121,0.00047824162,0.08478839,0.0009504157,0.0011457502,0.019233676,0.0035780254,0.009724918,0.8141119],"study_design_scores_gemma":[0.0028746738,0.010570489,0.3089724,0.0027828345,0.0012423743,0.4812349,0.001514511,0.003431976,0.007878733,0.0060196854,0.1733516,0.00012579246],"about_ca_topic_score_codex":0.000919838,"about_ca_topic_score_gemma":0.004437667,"teacher_disagreement_score":0.0012370505,"about_ca_system_score_codex":0.00041544548,"about_ca_system_score_gemma":0.0005001301,"threshold_uncertainty_score":0.0030142665},"labels":[],"label_agreement":null},{"id":"W2045089703","doi":"10.1097/00002826-200307000-00013","title":"Metabolite Changes Resulting From Treatment in Children With ADHD: A 1H-MRS Study","year":2003,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Institute for Biodiagnostics; Dalhousie University; Izaak Walton Killam Health Centre; Nova Scotia Health Authority","funders":"Eli Lilly Canada; Nova Scotia Health Research Foundation","keywords":"Phosphocreatine; Creatine; Glutamine; Metabolite; Striatum; Choline; Glutamate receptor; Neurochemical; Internal medicine; Glutamatergic; Attention deficit hyperactivity disorder; Medicine; Endocrinology; Ventral striatum; Psychology; Chemistry; Biochemistry; Dopamine; Psychiatry; Amino acid","score_opus":0.12134737887379468,"score_gpt":0.4435567764725035,"score_spread":0.3222093975987088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045089703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993969,0.0002169739,0.000053899577,0.000028178258,0.0000027702836,0.000009585817,0.00008684408,0.000004273136,0.0002006453],"genre_scores_gemma":[0.99882,0.0003365591,0.00028802152,0.000057598474,0.000008848804,0.000016994183,0.0002465884,0.000005192254,0.00022018813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99975663,0.000047891044,0.00002259582,0.00004020603,0.000070741386,0.0000618094],"domain_scores_gemma":[0.99966204,0.00006122312,0.00014611379,0.000013979162,0.000050980514,0.00006567532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018889125,0.00039782663,0.00079789315,0.0005074046,0.00062846823,0.00031622368,0.0002089062,0.0006678378,0.00079555175],"category_scores_gemma":[0.0010559915,0.00032967245,0.0004126421,0.00058672234,0.0004617991,0.00020449814,0.00021134462,0.00076075905,0.00015941911],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002952866,0.0010122767,0.9450971,0.00018299998,0.00028553177,0.007209879,0.0012088147,0.00020385552,0.02525712,0.000042121355,0.0003792336,0.016168233],"study_design_scores_gemma":[0.00006985883,0.0014646247,0.9877416,0.000009689374,0.00014226421,0.006617029,0.0005032394,0.00011983354,0.0027483972,0.00001837565,0.0005552372,0.00000990482],"about_ca_topic_score_codex":0.01047211,"about_ca_topic_score_gemma":0.013454257,"teacher_disagreement_score":0.01047211,"about_ca_system_score_codex":0.00084687554,"about_ca_system_score_gemma":0.00045209902,"threshold_uncertainty_score":0.020822346},"labels":[],"label_agreement":null},{"id":"W2045278212","doi":"10.1097/00002826-200403000-00004","title":"Dopaminergic Properties and Experimental Anti-Parkinsonian Effects of IPX750 in Rodent Models of Parkinson Disease","year":2004,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Nuclear Receptors and Signaling","field":"Neuroscience","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Neurological Disorders and Stroke; National Institutes of Health","keywords":"Dopaminergic; Dopamine transporter; Dopamine; Pharmacology; Chemistry; Dopamine Plasma Membrane Transport Proteins; Agonist; Biochemistry; Biology; Receptor; Neuroscience","score_opus":0.0680360821334167,"score_gpt":0.3304043789368377,"score_spread":0.262368296803421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045278212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98603684,0.005591888,0.0016578847,0.0002972701,0.00012357059,0.00024596378,0.0020366644,0.00019722171,0.0038126765],"genre_scores_gemma":[0.9728812,0.0068105133,0.0031907863,0.00021568422,0.00008027956,0.00045239693,0.0037493352,0.000034894125,0.012584831],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997565,0.0000338723,0.000025301722,0.000048326663,0.00006324559,0.00007278899],"domain_scores_gemma":[0.99983275,0.000013818132,0.00005200134,0.000018010353,0.00001847625,0.000064944485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003592796,0.0010798014,0.0004386262,0.001074878,0.0003814146,0.00039745797,0.00047161654,0.000703626,0.0024918588],"category_scores_gemma":[0.0001564893,0.0002856685,0.0005459077,0.0003420023,0.00061537395,0.0005422183,0.00015079054,0.0014887757,0.0004996443],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027782957,0.0021937934,0.0005817807,0.0002473482,0.000060879513,0.00026419165,0.00007906024,0.00020224969,0.9854139,0.0003236376,0.00048687286,0.007368034],"study_design_scores_gemma":[0.00045331326,0.025931539,0.011585296,0.000045113164,0.00018983301,0.00053518906,0.00013872198,0.0010918344,0.95519984,0.00018303723,0.004618898,0.000027419072],"about_ca_topic_score_codex":0.0023669412,"about_ca_topic_score_gemma":0.005918987,"teacher_disagreement_score":0.0024918588,"about_ca_system_score_codex":0.00072977727,"about_ca_system_score_gemma":0.00047166483,"threshold_uncertainty_score":0.008336127},"labels":[],"label_agreement":null},{"id":"W2047508973","doi":"10.1097/00002826-200601000-00009","title":"Augmentation Strategies of Clozapine With Antipsychotics in the Treatment of Ultraresistant Schizophrenia","year":2006,"lang":"en","type":"review","venue":"Clinical Neuropharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Unit on Children's Psychosocial Maladjustment","funders":"","keywords":"Clozapine; Schizophrenia (object-oriented programming); Antipsychotic; Medicine; Clinical trial; Refractory (planetary science); Psychiatry; Antipsychotic Agent; Psychology; Internal medicine","score_opus":0.14178545408663923,"score_gpt":0.49103547386675445,"score_spread":0.3492500197801152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047508973","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00046375435,0.9992455,0.000024559686,0.000035466768,0.000020018058,0.0000074262102,0.0000042918,0.000002491087,0.000196501],"genre_scores_gemma":[0.0043212953,0.99526864,0.00020588032,0.00006497623,0.000034911063,0.000013484094,0.000010838185,7.193351e-7,0.00007911095],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9994844,0.0002147424,0.00011425381,0.00004446738,0.00012106477,0.000021005804],"domain_scores_gemma":[0.9992907,0.00044475324,0.00016861074,0.000013326197,0.00005687962,0.000025854632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011682037,0.0006920841,0.0016015979,0.002598732,0.00020360822,0.0005339231,0.0008903378,0.0007422069,0.0017717328],"category_scores_gemma":[0.0016088655,0.00026411092,0.00089040824,0.002375592,0.00038199936,0.00053377426,0.00035273694,0.0004279954,0.00036411177],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007204404,0.000099605546,0.0005030677,0.13843791,0.0009497564,0.00066431065,0.00017771026,0.0003147182,0.0020133476,0.0007041821,0.0042897235,0.85112536],"study_design_scores_gemma":[0.0022332652,0.002947785,0.021454928,0.14023189,0.0140395,0.01975489,0.0010310906,0.0007728211,0.0063090557,0.0027327905,0.7883445,0.00014752291],"about_ca_topic_score_codex":0.0019808607,"about_ca_topic_score_gemma":0.0049981875,"teacher_disagreement_score":0.002598732,"about_ca_system_score_codex":0.0005820861,"about_ca_system_score_gemma":0.0011895446,"threshold_uncertainty_score":0.0061781406},"labels":[],"label_agreement":null},{"id":"W2049816046","doi":"10.1097/00002826-200201000-00005","title":"A Double-Blind Crossover, Placebo-Controlled Study of the Adenosine A2A Antagonist Theophylline in Parkinson's Disease","year":2002,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"","keywords":"Theophylline; Crossover study; Antagonist; Placebo; Medicine; Adenosine; Double blind; Anesthesia; Pharmacology; Internal medicine; Pathology","score_opus":0.05653257955031033,"score_gpt":0.35728820973786446,"score_spread":0.30075563018755413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049816046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874527,0.0035803907,0.0011397002,0.00031620698,0.00081430736,0.0046764617,0.00057608855,0.0001668044,0.0012772871],"genre_scores_gemma":[0.98442274,0.0021462296,0.0028498538,0.00078478013,0.00088373735,0.005770242,0.000674435,0.000031680884,0.0024362367],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987141,0.00055855874,0.00015099514,0.00029542303,0.0001183619,0.000162655],"domain_scores_gemma":[0.9984017,0.0005446283,0.00025777085,0.00014958666,0.00013333486,0.0005129496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023740884,0.0016916945,0.004523976,0.00070430397,0.0008572245,0.0007771027,0.00084799185,0.0022138604,0.0038868445],"category_scores_gemma":[0.0026459543,0.00073829206,0.00095445383,0.00057834334,0.0019960355,0.0011738435,0.00041070327,0.0021471218,0.0007526496],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94315934,0.026619202,0.00067946326,0.0005935609,0.0004904961,0.00004838383,0.00012206562,0.00014841967,0.010641577,0.00009068612,0.00042001996,0.016986689],"study_design_scores_gemma":[0.71539545,0.27807584,0.003973602,0.000021099744,0.00024254517,0.000034803325,0.000027003305,0.0002795045,0.0011336093,0.00010069495,0.00069628435,0.000019504734],"about_ca_topic_score_codex":0.0005266831,"about_ca_topic_score_gemma":0.00079683017,"teacher_disagreement_score":0.004523976,"about_ca_system_score_codex":0.00044252927,"about_ca_system_score_gemma":0.0009556026,"threshold_uncertainty_score":0.013002813},"labels":[],"label_agreement":null},{"id":"W2051115769","doi":"10.1097/00002826-200107000-00004","title":"Comparison of Two Dosages of Tolcapone Added to Levodopa in Nonfluctuating Patients with PD","year":2001,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus; Roche (Canada); University of Calgary; Saint John Regional Hospital; Dalhousie University","funders":"","keywords":"Dose; Adverse effect; Levodopa; Nausea; Crossover study; Medicine; Dyskinesia; Tolerability; Anesthesia; Placebo; Internal medicine; Parkinson's disease; Disease","score_opus":0.07501022924080697,"score_gpt":0.4547305578632965,"score_spread":0.37972032862248956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051115769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966815,0.0020663377,0.00013822407,0.00010095047,0.000113064336,0.00030453832,0.00013159393,0.000030090954,0.00043372548],"genre_scores_gemma":[0.9971865,0.0009795739,0.00041803365,0.0001760277,0.0001936951,0.00031818793,0.00029128257,0.000006473409,0.0004302741],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9990195,0.0005025078,0.00010042463,0.00016566983,0.000102144615,0.0001097049],"domain_scores_gemma":[0.9985489,0.0005508095,0.00025471614,0.00010889488,0.00007305984,0.0004635539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011952575,0.0011112721,0.0025322877,0.00066480896,0.00039863848,0.00092880736,0.00094442064,0.0015985765,0.0027370984],"category_scores_gemma":[0.0026714378,0.00069256546,0.0011630302,0.00042510018,0.0008867511,0.001020446,0.00033231362,0.002014691,0.00045550562],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9400276,0.013451686,0.002018847,0.0004177523,0.0006877411,0.00015813368,0.00011318627,0.00030098352,0.0066848113,0.000071060604,0.00022411758,0.035844017],"study_design_scores_gemma":[0.5685627,0.4205204,0.00832774,0.000034633405,0.00037058268,0.00011098047,0.000059365,0.00044677727,0.0010128916,0.00007490032,0.00044676726,0.00003226154],"about_ca_topic_score_codex":0.0006182448,"about_ca_topic_score_gemma":0.0016751622,"teacher_disagreement_score":0.0027370984,"about_ca_system_score_codex":0.0006397671,"about_ca_system_score_gemma":0.0004960499,"threshold_uncertainty_score":0.009156525},"labels":[],"label_agreement":null},{"id":"W2052643285","doi":"10.1097/00002826-200107000-00003","title":"Methylphenidate Increases the Motor Effects of L-Dopa in Parkinson's Disease: A Pilot Study","year":2001,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Center for Research Resources; National Institute of Neurological Disorders and Stroke","keywords":"Methylphenidate; Anxiety; Levodopa; Anesthesia; Psychology; Dyskinesia; Mood; Dopamine; Placebo; Carbidopa; Stroop effect; Medicine; Parkinson's disease; Cognition; Psychiatry; Internal medicine; Attention deficit hyperactivity disorder; Neuroscience; Disease","score_opus":0.05245199753721957,"score_gpt":0.38186141014338154,"score_spread":0.32940941260616197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052643285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971973,0.0017483605,0.00009037701,0.000074315016,0.000038440274,0.00015369132,0.00010169018,0.00001754486,0.00057836925],"genre_scores_gemma":[0.99710864,0.001422809,0.00029966203,0.00013944805,0.00008379152,0.0001002161,0.0002905715,0.0000067446854,0.000548063],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99976975,0.00008738134,0.000022967368,0.00002718735,0.000039765924,0.00005288289],"domain_scores_gemma":[0.9996025,0.00010936204,0.0000480225,0.000030519135,0.000037020647,0.00017255083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053950946,0.00081598735,0.0012688562,0.00026823083,0.00041841576,0.00033932299,0.00045492526,0.00081142195,0.0022390469],"category_scores_gemma":[0.00073304423,0.00026425824,0.0006711115,0.00022105883,0.00044324403,0.00044149888,0.000267015,0.0009862657,0.00040355884],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36465594,0.045273144,0.01604121,0.0011136374,0.0013550775,0.0031091466,0.00040622344,0.00033657908,0.42597142,0.0000972647,0.00103963,0.1406008],"study_design_scores_gemma":[0.06568446,0.7622157,0.122908145,0.00006603261,0.0013963188,0.0023140577,0.00019111177,0.0007552824,0.039853327,0.00008932763,0.0044844165,0.000041845462],"about_ca_topic_score_codex":0.0015937308,"about_ca_topic_score_gemma":0.003838751,"teacher_disagreement_score":0.0022390469,"about_ca_system_score_codex":0.00026679132,"about_ca_system_score_gemma":0.00049626554,"threshold_uncertainty_score":0.007490337},"labels":[],"label_agreement":null},{"id":"W2054808759","doi":"10.1097/00002826-200305000-00005","title":"Medications and Substances as a Cause of Headache: A Systematic Review of the Literature","year":2003,"lang":"en","type":"review","venue":"Clinical Neuropharmacology","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Etiology; Medicine; Intensive care medicine; Headaches; Identification (biology); Psychiatry; Biology","score_opus":0.11124576283670541,"score_gpt":0.501474342080962,"score_spread":0.3902285792442566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054808759","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007768962,0.9986998,0.000030037287,0.00008423603,0.00005240125,0.00002452774,0.00007019991,0.0000017458922,0.00026020815],"genre_scores_gemma":[0.0033523613,0.996201,0.0001489728,0.000102986145,0.0000412328,0.000025399158,0.000039517632,4.4256797e-7,0.0000880301],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9987966,0.00031552027,0.0004678553,0.00010647535,0.0002690046,0.000044634315],"domain_scores_gemma":[0.99681073,0.001989811,0.00075041124,0.000034782002,0.00035395604,0.00006021529],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001205936,0.0008015786,0.002904359,0.0069135157,0.00038486748,0.0009912447,0.000797094,0.0009862666,0.003663409],"category_scores_gemma":[0.0040381523,0.0004091612,0.0014509984,0.009948993,0.0004038883,0.0012957656,0.00052879885,0.0003535564,0.0004483019],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040307036,0.000081997874,0.0051973113,0.59598786,0.002678116,0.003642321,0.00056326203,0.00022575077,0.0007223411,0.000503422,0.012367468,0.37762707],"study_design_scores_gemma":[0.00046909525,0.0008299297,0.05286074,0.5880871,0.03731852,0.028553637,0.002602815,0.00029318916,0.00094746385,0.0009944395,0.28692576,0.000117330084],"about_ca_topic_score_codex":0.0057637375,"about_ca_topic_score_gemma":0.01643381,"teacher_disagreement_score":0.0069135157,"about_ca_system_score_codex":0.0010152928,"about_ca_system_score_gemma":0.0039610774,"threshold_uncertainty_score":0.012255371},"labels":[],"label_agreement":null},{"id":"W2057903762","doi":"10.1097/00002826-200003000-00007","title":"Clinical, Pharmacokinetic, and Pharmacodynamic Effects of Tolcapone Withdrawal in Levodopa-Treated Patients with Parkinsonism","year":2000,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AXYS Technologies (Canada)","funders":"","keywords":"Levodopa; Discontinuation; Placebo; Pharmacodynamics; Parkinsonism; Pharmacokinetics; Adverse effect; Catechol-O-methyl transferase; Anesthesia; Medicine; Pharmacology; Internal medicine; Psychology; Parkinson's disease; Chemistry","score_opus":0.012767362848147277,"score_gpt":0.3311193104999585,"score_spread":0.31835194765181124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057903762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984149,0.0009889823,0.00006262099,0.000053247662,0.000008714263,0.00003658538,0.00007102211,0.0000053145463,0.00035861353],"genre_scores_gemma":[0.99940884,0.00022619143,0.000055885477,0.00006631681,0.000016061007,0.000019403635,0.00011128526,0.0000010350287,0.00009500848],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99958116,0.00017452065,0.000057041158,0.000053205033,0.0000800879,0.000053989315],"domain_scores_gemma":[0.99883884,0.00046435985,0.000306706,0.000036867266,0.000072322546,0.00028094213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055405067,0.00041274205,0.0010366658,0.00027812057,0.0004137456,0.00033516125,0.00018845969,0.00044128788,0.0008919707],"category_scores_gemma":[0.0021615834,0.00021684075,0.0005959597,0.00035460922,0.00030825546,0.00023514075,0.000173214,0.0006025419,0.00011939427],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21991895,0.0032706384,0.5944818,0.0006339009,0.001527748,0.003188345,0.00050857686,0.0011361892,0.048082583,0.00007129169,0.0006833701,0.12649663],"study_design_scores_gemma":[0.009605004,0.058859296,0.9244191,0.000041884832,0.00051131827,0.0019329081,0.00014106934,0.0007494284,0.00268922,0.00009201469,0.0009245542,0.000034185956],"about_ca_topic_score_codex":0.00087047776,"about_ca_topic_score_gemma":0.0023684718,"teacher_disagreement_score":0.0010366658,"about_ca_system_score_codex":0.00047586154,"about_ca_system_score_gemma":0.00034376816,"threshold_uncertainty_score":0.0034526587},"labels":[],"label_agreement":null},{"id":"W2068802937","doi":"10.1097/00002826-200601000-00010","title":"Somatic Augmentation Strategies in Clozapine Resistance-What Facts?","year":2006,"lang":"en","type":"review","venue":"Clinical Neuropharmacology","topic":"Electroconvulsive Therapy Studies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Clozapine; Polypharmacy; Tolerability; Medicine; Electroconvulsive therapy; Rotigotine; Clinical trial; Transcranial magnetic stimulation; Psychiatry; Psychology; Pharmacology; Adverse effect; Internal medicine; Stimulation; Disease; Schizophrenia (object-oriented programming)","score_opus":0.14261878684771034,"score_gpt":0.5178340429518419,"score_spread":0.37521525610413153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068802937","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022989395,0.99905545,0.000020012227,0.00028168777,0.0000502415,0.000003580017,0.000004816493,0.0000020122893,0.0003522861],"genre_scores_gemma":[0.0023632299,0.9970387,0.00012136706,0.00021899096,0.00009198561,0.000008681322,0.000008239244,6.231951e-7,0.00014816497],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996383,0.00013853543,0.00008368419,0.000030567477,0.000087569395,0.000021321575],"domain_scores_gemma":[0.9993,0.00044804753,0.00014248281,0.000017398777,0.000073040435,0.0000190767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001079668,0.0005733895,0.001724034,0.0014477975,0.00020755136,0.0009646271,0.0008934763,0.0015668775,0.0038601037],"category_scores_gemma":[0.0020179457,0.00022661644,0.000768088,0.0018947807,0.00045189113,0.0011911155,0.00028871902,0.00071413897,0.0009519954],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030718266,0.00006710066,0.0003378755,0.074101076,0.0003184164,0.0006274109,0.00013698354,0.0001356734,0.000599286,0.0012407012,0.007906823,0.91422147],"study_design_scores_gemma":[0.0010747464,0.001186537,0.0104205515,0.18215391,0.004059154,0.018417245,0.0015394232,0.00040479377,0.0021120864,0.004546217,0.7739962,0.00008920916],"about_ca_topic_score_codex":0.001985883,"about_ca_topic_score_gemma":0.0053288355,"teacher_disagreement_score":0.0038601037,"about_ca_system_score_codex":0.00051618717,"about_ca_system_score_gemma":0.0010903566,"threshold_uncertainty_score":0.012913346},"labels":[],"label_agreement":null},{"id":"W2084409189","doi":"10.1097/00002826-200005000-00003","title":"The Relationship between COMT Genotype and the Clinical Effectiveness of Tolcapone, a COMT Inhibitor, in Patients with Parkinson's Disease","year":2000,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Catechol-O-methyl transferase; Genotype; Levodopa; Internal medicine; Parkinson's disease; Clinical trial; Gastroenterology; Medicine; Psychology; Disease; Biology; Genetics; Gene","score_opus":0.041466851835363444,"score_gpt":0.3644804545033011,"score_spread":0.32301360266793766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084409189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99930084,0.00037508277,0.000042871394,0.000029458417,0.000004850704,0.0000035925261,0.00005546362,0.0000027917959,0.00018501474],"genre_scores_gemma":[0.999681,0.000061234976,0.00004934951,0.000020915535,0.0000068096056,0.00000238776,0.00007749491,0.0000012981457,0.000099638186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99937147,0.0002493835,0.00010737283,0.000099564975,0.000116702584,0.00005546977],"domain_scores_gemma":[0.9967218,0.0014148469,0.0010783806,0.00020500805,0.00022143159,0.00035850029],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007640808,0.00029473647,0.00050340634,0.0002804804,0.00024015398,0.00044984045,0.00015505243,0.00046676147,0.0005737582],"category_scores_gemma":[0.004089499,0.00019545988,0.0003942395,0.00031552833,0.0001964966,0.00027514712,0.00014917024,0.00043008986,0.00015469624],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055888165,0.00018923676,0.98310053,0.000026839225,0.00041175736,0.00022506567,0.00007186824,0.0003515052,0.0022841685,0.000009071954,0.00008389054,0.007657299],"study_design_scores_gemma":[0.00006858759,0.0014721993,0.9972379,0.00000292827,0.00009330341,0.00037640386,0.000030897343,0.00036111567,0.00025510738,0.000014743609,0.00008147558,0.000005317269],"about_ca_topic_score_codex":0.00095895806,"about_ca_topic_score_gemma":0.0019128823,"teacher_disagreement_score":0.00095895806,"about_ca_system_score_codex":0.00029799028,"about_ca_system_score_gemma":0.00013709268,"threshold_uncertainty_score":0.004040897},"labels":[],"label_agreement":null},{"id":"W2085470371","doi":"10.1097/00002826-200307000-00007","title":"Pharmacokinetic Studies of Single and Multiple Oral Doses of Fampridine-SR (Sustained-Release 4-Aminopyridine) in Patients With Chronic Spinal Cord Injury","year":2003,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Spinal Cord Injury Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Lawson Health Research Institute; Western University","funders":"","keywords":"Pharmacokinetics; 4-Aminopyridine; Medicine; Dosing; Spinal cord injury; Adverse effect; Anesthesia; Oral administration; Spinal cord; Pharmacology; Internal medicine","score_opus":0.11361574447785358,"score_gpt":0.4635978927958428,"score_spread":0.34998214831798924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085470371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99635637,0.0021348998,0.00073112367,0.000070906644,0.000017976852,0.0001108691,0.00013718306,0.00003168898,0.0004089482],"genre_scores_gemma":[0.99735355,0.00090414326,0.00084387447,0.00012058922,0.00006158778,0.00014651143,0.00027754187,0.000008875412,0.00028326592],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994961,0.00021978145,0.000042467273,0.00009670204,0.00009805004,0.000046921978],"domain_scores_gemma":[0.9987871,0.0003713744,0.00032986302,0.000089822825,0.00013232231,0.0002895932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008574259,0.00046921708,0.0013313853,0.00027342146,0.00032608648,0.00039456677,0.00022985271,0.0006473039,0.00080231944],"category_scores_gemma":[0.0028167446,0.0002787109,0.0005023731,0.00034481357,0.000444847,0.00046615658,0.00016356776,0.0009345431,0.0002581255],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26820377,0.014084794,0.11370661,0.0012336627,0.0025291448,0.00201606,0.0017934919,0.0056566037,0.3379458,0.00031985427,0.0022870707,0.25022322],"study_design_scores_gemma":[0.028664306,0.54167634,0.37285075,0.00007476415,0.0013241726,0.0052629076,0.0003839084,0.008742353,0.03403828,0.00022104045,0.0066139563,0.00014726154],"about_ca_topic_score_codex":0.0008811204,"about_ca_topic_score_gemma":0.0008220961,"teacher_disagreement_score":0.0013313853,"about_ca_system_score_codex":0.0004308326,"about_ca_system_score_gemma":0.00063378015,"threshold_uncertainty_score":0.0045345426},"labels":[],"label_agreement":null},{"id":"W2085751814","doi":"10.1097/01.wnf.0000220823.80640.44","title":"Topiramate-induced Psychosis in Patients with Essential Tremor","year":2006,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Neurological disorders and treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"","keywords":"Topiramate; Paranoia; Psychosis; Psychiatry; Medicine; Essential tremor; Adverse effect; Psychology; Pediatrics; Epilepsy; Internal medicine","score_opus":0.026736962377278472,"score_gpt":0.36043257346560914,"score_spread":0.3336956110883307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085751814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99668413,0.0008260535,0.00016068039,0.00019934865,0.00001925022,0.000043609427,0.00004198067,0.00001740106,0.0020074737],"genre_scores_gemma":[0.9994072,0.00022852188,0.00007357136,0.00010563445,0.000019547248,0.0000056156546,0.00003199144,0.000001569868,0.00012644223],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99965763,0.000077855475,0.000050393992,0.000033695367,0.000081945094,0.000098459095],"domain_scores_gemma":[0.9994374,0.00017445677,0.00014344881,0.00003057894,0.000038895174,0.00017527693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033068162,0.0005154914,0.000519945,0.0005781053,0.0008408389,0.00052927714,0.00025400912,0.0007676646,0.0009381374],"category_scores_gemma":[0.0022978364,0.0003990991,0.0006490156,0.00036602735,0.00036302797,0.00042469974,0.00033620116,0.0008104684,0.00020152192],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071503134,0.00092959753,0.72277415,0.00036602092,0.00031237552,0.19809677,0.0028191134,0.00051250565,0.016368326,0.0003694222,0.0011222538,0.04917913],"study_design_scores_gemma":[0.001442622,0.0060531055,0.7727864,0.00010815926,0.0004343034,0.21092075,0.0012734142,0.0017563591,0.0023330762,0.00058429677,0.002230888,0.000076586904],"about_ca_topic_score_codex":0.0029431765,"about_ca_topic_score_gemma":0.0055802953,"teacher_disagreement_score":0.0029431765,"about_ca_system_score_codex":0.0006440296,"about_ca_system_score_gemma":0.0004941659,"threshold_uncertainty_score":0.0058521032},"labels":[],"label_agreement":null},{"id":"W2087320487","doi":"10.1097/00002826-200203000-00002","title":"Treatment of Patients With Tardive Dystonia With Olanzapine","year":2002,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Spasmodic Torticollis; Cervical dystonia; Dystonia; Olanzapine; Torticollis; Rating scale; Visual analogue scale; Anesthesia; Psychology; Medicine; Schizophrenia (object-oriented programming); Surgery; Psychiatry","score_opus":0.042686683972505066,"score_gpt":0.32332059350321185,"score_spread":0.28063390953070677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087320487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985896,0.00071562896,0.00013569524,0.00004254338,0.00001237737,0.0000797201,0.000035099645,0.000012511143,0.00037672604],"genre_scores_gemma":[0.9985763,0.0004047324,0.0005409963,0.0000922553,0.000026116351,0.00007192707,0.00011971011,0.0000029064806,0.00016513851],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99979705,0.000068058805,0.000038785285,0.000027081192,0.000034548033,0.00003456497],"domain_scores_gemma":[0.9996426,0.0000971417,0.000089222616,0.000033282744,0.000027182128,0.00011047614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038183716,0.00045996136,0.0009725981,0.00021446854,0.000399555,0.0002581538,0.00026489064,0.00036409995,0.0005772422],"category_scores_gemma":[0.0010745396,0.00015506515,0.00044281664,0.0001821645,0.00023046782,0.00023354766,0.00018402778,0.00046620483,0.0001529358],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19146696,0.012284059,0.23319961,0.0011085975,0.0011195125,0.016808229,0.0018904101,0.0017185808,0.23159938,0.00019518219,0.0017448174,0.30686468],"study_design_scores_gemma":[0.027263459,0.26153177,0.66067225,0.00013198939,0.00084337295,0.020971818,0.0009704535,0.0039144647,0.01809524,0.0003006485,0.005179596,0.00012494838],"about_ca_topic_score_codex":0.0012260614,"about_ca_topic_score_gemma":0.003350167,"teacher_disagreement_score":0.0012260614,"about_ca_system_score_codex":0.00044340483,"about_ca_system_score_gemma":0.0003567092,"threshold_uncertainty_score":0.003217101},"labels":[],"label_agreement":null},{"id":"W2087720405","doi":"10.1097/wnf.0000000000000034","title":"Liquid Melevodopa Versus Standard Levodopa in Patients With Parkinson Disease and Small Intestinal Bacterial Overgrowth","year":2014,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Gastrointestinal motility and disorders","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders; University of Toronto","funders":"","keywords":"Levodopa; Small intestinal bacterial overgrowth; Bacterial overgrowth; Medicine; Parkinson's disease; Gastroenterology; Disease; Internal medicine","score_opus":0.03021068418300843,"score_gpt":0.3101651354656374,"score_spread":0.27995445128262897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087720405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99868196,0.0010440605,0.000023189958,0.00003210363,0.0000098555065,0.000016000942,0.000026424454,0.0000030563274,0.00016320866],"genre_scores_gemma":[0.99935156,0.0002700545,0.00011673455,0.00004989402,0.000019429075,0.000026548398,0.000060809594,7.074247e-7,0.000104360224],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998149,0.00007656625,0.000026312571,0.000028636841,0.000026955084,0.000026640031],"domain_scores_gemma":[0.9995011,0.00019535153,0.000093283124,0.000016150598,0.000023607654,0.00017054763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042437192,0.00032647065,0.000992373,0.00017596457,0.00025061003,0.0003142225,0.00015961897,0.0003897935,0.0012720429],"category_scores_gemma":[0.0010293454,0.00012309043,0.0004970448,0.00014262348,0.00020529954,0.00030354384,0.00021506628,0.0004082612,0.00013963261],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71403843,0.008227832,0.14502074,0.0006298779,0.001152612,0.0006401526,0.00037135094,0.0006534465,0.018602483,0.00008062567,0.00053748325,0.1100449],"study_design_scores_gemma":[0.039406132,0.4635772,0.48378766,0.00013361473,0.0014861423,0.0013042778,0.0005764347,0.0033737165,0.004366815,0.00016629738,0.001769542,0.00005225511],"about_ca_topic_score_codex":0.00046082525,"about_ca_topic_score_gemma":0.0011963453,"teacher_disagreement_score":0.0012720429,"about_ca_system_score_codex":0.00026752005,"about_ca_system_score_gemma":0.00026552708,"threshold_uncertainty_score":0.004255414},"labels":[],"label_agreement":null},{"id":"W2088003671","doi":"10.1097/00002826-200109000-00003","title":"Acute Spinal Cord Injury, Part II: Contemporary Pharmacotherapy","year":2001,"lang":"en","type":"review","venue":"Clinical Neuropharmacology","topic":"Spinal Cord Injury Research","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia","funders":"","keywords":"Medicine; Spinal cord injury; Methylprednisolone; Pharmacology; Spinal cord; Anesthesia","score_opus":0.42886155007232385,"score_gpt":0.6179216795098523,"score_spread":0.18906012943752848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088003671","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011627281,0.9782814,0.00097074633,0.0063504623,0.0009021081,0.000066379354,0.00006532786,0.000039051298,0.012161927],"genre_scores_gemma":[0.0047572586,0.98536575,0.0012627405,0.0032890267,0.0016440499,0.000090075024,0.00009817262,0.000011704335,0.0034811092],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99966633,0.00008932511,0.000054724864,0.000053779615,0.00010413219,0.000031675918],"domain_scores_gemma":[0.99959904,0.00012237208,0.00006813591,0.000024879799,0.00012762635,0.000057988225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006355431,0.0006640434,0.0009301902,0.0019376959,0.0004056778,0.0018491503,0.0006271725,0.0011074566,0.006744015],"category_scores_gemma":[0.0009808022,0.00021121086,0.00049582653,0.0018445881,0.0007433259,0.0015030061,0.0008426174,0.0021788608,0.0025497116],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001335613,0.00030772918,0.00048765788,0.004400264,0.000068358015,0.00018088086,0.000105836305,0.00037505504,0.001252357,0.0069708126,0.037809834,0.9479076],"study_design_scores_gemma":[0.00012208235,0.0005729002,0.0064138323,0.0066595008,0.0001229153,0.0026212567,0.00022860816,0.0004416142,0.00056812697,0.0093687065,0.972843,0.000037566642],"about_ca_topic_score_codex":0.0015278683,"about_ca_topic_score_gemma":0.003359526,"teacher_disagreement_score":0.006744015,"about_ca_system_score_codex":0.0011224631,"about_ca_system_score_gemma":0.0013870926,"threshold_uncertainty_score":0.022561014},"labels":[],"label_agreement":null},{"id":"W2094809640","doi":"10.1097/wnf.0b013e3181f0f013","title":"Quetiapine Combined With Amisulpride in Schizophrenic Patients With Insufficient Responses to Quetiapine Monotherapy","year":2010,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Amisulpride; Quetiapine; Olanzapine; Clozapine; Schizophrenia (object-oriented programming); Scale for the Assessment of Negative Symptoms; Positive and Negative Syndrome Scale; Medicine; Atypical antipsychotic; Internal medicine; Quetiapine Fumarate; Antipsychotic; Pharmacology; Psychology; Psychiatry; Brief Psychiatric Rating Scale; Psychosis","score_opus":0.02345249139775351,"score_gpt":0.3661104584676639,"score_spread":0.34265796706991036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094809640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99427515,0.0028780578,0.00036216291,0.00035685254,0.000047334044,0.00006590509,0.00007106237,0.00005722986,0.0018862509],"genre_scores_gemma":[0.9987437,0.0005911122,0.00020168017,0.00013217468,0.00004086439,0.000010630722,0.000059701888,0.000004408739,0.00021581668],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99972755,0.00008123634,0.000042449,0.000045783338,0.000048739268,0.000054243214],"domain_scores_gemma":[0.99961144,0.000086467655,0.00010827666,0.000027071645,0.000022683536,0.00014406322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041315795,0.0007245858,0.0010410656,0.00052016287,0.00061398605,0.0003707595,0.00036608806,0.0007632257,0.0009901918],"category_scores_gemma":[0.0011264982,0.00026328853,0.0006786288,0.0004488054,0.00038923058,0.00028264296,0.00023520848,0.0006740954,0.00034109954],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029341234,0.0028317736,0.42186832,0.0009466303,0.0012478712,0.23002446,0.0022452034,0.001463041,0.1351625,0.0006197269,0.0022617318,0.17198752],"study_design_scores_gemma":[0.0032092454,0.02980657,0.6943947,0.00019984672,0.0014879683,0.24318193,0.0010246561,0.0040732473,0.015224061,0.0006139637,0.006635799,0.00014802707],"about_ca_topic_score_codex":0.002484663,"about_ca_topic_score_gemma":0.0056013525,"teacher_disagreement_score":0.002484663,"about_ca_system_score_codex":0.0007792962,"about_ca_system_score_gemma":0.0006014784,"threshold_uncertainty_score":0.0056542754},"labels":[],"label_agreement":null},{"id":"W2095110740","doi":"10.1097/wnf.0b013e31802fa61a","title":"Oral Cholinesterase Inhibitor Add-on Therapy for Cognitive Enhancement in Schizophrenia","year":2007,"lang":"en","type":"review","venue":"Clinical Neuropharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Louis-H Lafontaine; Université du Québec à Montréal","funders":"","keywords":"Neurocognitive; Schizophrenia (object-oriented programming); Cognition; Psychology; Executive functions; Physical medicine and rehabilitation; Medicine; Psychiatry","score_opus":0.2847984843581851,"score_gpt":0.5543568871014394,"score_spread":0.26955840274325427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095110740","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011452539,0.9832041,0.00034225185,0.0011422907,0.00026718862,0.0009683546,0.0006932812,0.000016437318,0.0019135207],"genre_scores_gemma":[0.1531161,0.8387079,0.0026002603,0.0025563608,0.00042444686,0.0012848398,0.00077279017,0.0000094685165,0.000527825],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99715185,0.0014826313,0.0007157062,0.00015377786,0.0004307623,0.000065268636],"domain_scores_gemma":[0.9934384,0.004463611,0.0016278641,0.000093164555,0.00028762128,0.00008923723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005348172,0.0005168715,0.0023088357,0.0029660647,0.00022403945,0.0012998149,0.00070805044,0.0009972265,0.0058323443],"category_scores_gemma":[0.014025198,0.0002584131,0.0032462212,0.0019836277,0.00048395974,0.0006764956,0.0005838806,0.0009155492,0.0003405293],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00863378,0.0003505372,0.00344259,0.6441267,0.02455919,0.00032401894,0.00014415242,0.00053421006,0.0011527196,0.0010838888,0.0036968943,0.31195128],"study_design_scores_gemma":[0.031490453,0.011311929,0.047797523,0.6234513,0.21846493,0.0017588453,0.0006240472,0.0010568793,0.0025259156,0.004298231,0.057035193,0.00018486328],"about_ca_topic_score_codex":0.0021111218,"about_ca_topic_score_gemma":0.0075783487,"teacher_disagreement_score":0.0058323443,"about_ca_system_score_codex":0.0014054959,"about_ca_system_score_gemma":0.0022258274,"threshold_uncertainty_score":0.028284192},"labels":[],"label_agreement":null},{"id":"W2109594309","doi":"10.1097/01.wnf.0000236763.16032.60","title":"Plasma Homocysteine Levels and Parkinson Disease","year":2006,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Folate and B Vitamins Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Internal medicine; Montreal Cognitive Assessment; Medicine; Homocysteine; Parkinson's disease; Depression (economics); Psychosis; Dementia; Rating scale; Beck Depression Inventory; Gastroenterology; Disease; Psychology; Psychiatry","score_opus":0.07257440747081113,"score_gpt":0.41383714245636805,"score_spread":0.3412627349855569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109594309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99634165,0.0029079693,0.000047111393,0.000052063726,0.0000059038566,0.00000402724,0.0001625116,0.0000048526995,0.00047395364],"genre_scores_gemma":[0.9990662,0.00039938063,0.00012046417,0.000036619756,0.000015038883,0.000005709445,0.00016891016,0.0000012300857,0.00018649868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998178,0.00004593031,0.000031969437,0.000044916036,0.00003837932,0.000021027323],"domain_scores_gemma":[0.99925715,0.00018821027,0.0003274507,0.000015228996,0.00009456535,0.00011736836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023998688,0.00024787724,0.00039102448,0.000488625,0.0003046766,0.0004420516,0.00010553025,0.0005280189,0.0017547582],"category_scores_gemma":[0.001177316,0.00012368413,0.000112489215,0.0004191068,0.0001691275,0.000174838,0.0001900241,0.00032506403,0.00021733501],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001148014,0.00008904751,0.9883377,0.0001017656,0.00014117036,0.0004895951,0.00012426072,0.000068308116,0.0024424603,0.000021274709,0.00019919265,0.0068371273],"study_design_scores_gemma":[0.00001842277,0.00031330375,0.99725926,0.000019670482,0.000048030055,0.001584071,0.00006351938,0.00011138977,0.0002684971,0.00002976066,0.00028035263,0.000003806844],"about_ca_topic_score_codex":0.00079259457,"about_ca_topic_score_gemma":0.0009435676,"teacher_disagreement_score":0.0017547582,"about_ca_system_score_codex":0.00015309118,"about_ca_system_score_gemma":0.0001424309,"threshold_uncertainty_score":0.0058702826},"labels":[],"label_agreement":null},{"id":"W2329026659","doi":"10.1097/wnf.0000000000000067","title":"Effect of Midazolam on Memory During Fiberoptic Gastroscopy Under Conscious Sedation","year":2015,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Anesthesia and Sedative Agents","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Midazolam; Sedation; Anesthesia; Medicine","score_opus":0.06420667134097428,"score_gpt":0.4356038684814592,"score_spread":0.3713971971404849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329026659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993299,0.00039532947,0.000043776137,0.000013236991,0.000004713879,0.000007877829,0.0000094959,0.0000035444518,0.00019212041],"genre_scores_gemma":[0.9996755,0.00013876642,0.000057091114,0.000020066474,0.000005476721,0.000005494875,0.000017501825,6.300683e-7,0.00007949527],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998816,0.000039081602,0.000011319616,0.000012690698,0.000026457808,0.00002883544],"domain_scores_gemma":[0.9995492,0.00012913482,0.0001627064,0.000029288844,0.000055948472,0.00007368793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016885567,0.00018273389,0.00024964206,0.00010243368,0.00011888305,0.00022409287,0.000115392504,0.0001776228,0.00064135616],"category_scores_gemma":[0.0013680605,0.000059111957,0.00013177331,0.000072786774,0.00020269182,0.00017082668,0.00014997934,0.00023255264,0.000057447385],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07822985,0.0029787265,0.1917894,0.00083520974,0.0003714508,0.003088961,0.0013645943,0.00030334567,0.57698166,0.00013345334,0.00042326632,0.14350016],"study_design_scores_gemma":[0.00082549173,0.065883,0.8630459,0.00006346936,0.00030947736,0.0021146757,0.00044772343,0.0009376548,0.065247476,0.00007704132,0.0010253164,0.000022839358],"about_ca_topic_score_codex":0.0006721552,"about_ca_topic_score_gemma":0.0010188639,"teacher_disagreement_score":0.0006721552,"about_ca_system_score_codex":0.00016184074,"about_ca_system_score_gemma":0.0002137367,"threshold_uncertainty_score":0.0021455288},"labels":[],"label_agreement":null},{"id":"W2330754946","doi":"10.1097/wnf.0b013e3182a5cb76","title":"Repeated Erythromycin/Codeine-Induced Psychotic Mania","year":2013,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Pharmacological Effects and Toxicity Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority","funders":"","keywords":"Mania; Erythromycin; Medicine; Codeine; Adverse effect; Psychiatry; Acetaminophen; Schizophrenia (object-oriented programming); Bipolar disorder; Anesthesia; Internal medicine; Antibiotics; Mood","score_opus":0.09852931102306338,"score_gpt":0.43880218417987715,"score_spread":0.34027287315681376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2330754946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97941965,0.005485721,0.0017056165,0.0005912587,0.0000988716,0.00014886186,0.00012021551,0.00011324835,0.0123164505],"genre_scores_gemma":[0.9968189,0.0010611848,0.00047896328,0.0004912511,0.00006900739,0.000011747181,0.0000467,0.0000098325245,0.0010122908],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99964094,0.00009174251,0.000061386476,0.000053126176,0.000087019085,0.00006587528],"domain_scores_gemma":[0.9987446,0.00031155435,0.00062331586,0.000076873024,0.00011316167,0.00013051064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018072817,0.00040751754,0.00037097358,0.0003479953,0.00040985513,0.00030333354,0.00026745375,0.00069949613,0.0016239756],"category_scores_gemma":[0.0018291544,0.00019646343,0.0003312319,0.00027229893,0.00036188145,0.00027412438,0.00031200188,0.00085699296,0.00040312862],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008230073,0.00024216501,0.086928524,0.00056642253,0.0001394536,0.82855207,0.00072375213,0.00018100516,0.05197819,0.00032972216,0.0011938881,0.02834186],"study_design_scores_gemma":[0.00006796323,0.001160766,0.11787853,0.000103576516,0.000090150235,0.8635503,0.00025929775,0.0004997633,0.011239844,0.0001586586,0.0049609332,0.00003014395],"about_ca_topic_score_codex":0.0012577208,"about_ca_topic_score_gemma":0.0024045317,"teacher_disagreement_score":0.0016239756,"about_ca_system_score_codex":0.00047610907,"about_ca_system_score_gemma":0.0002605039,"threshold_uncertainty_score":0.0054327846},"labels":[],"label_agreement":null},{"id":"W2332272503","doi":"10.1097/wnf.0b013e3181f5a5f9","title":"Bupropion for Depression in Schizophrenia","year":2010,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bupropion; Positive and Negative Syndrome Scale; Psychiatry; Psychology; Extrapyramidal symptoms; Tolerability; Schizophrenia (object-oriented programming); Antidepressant; Antipsychotic; Major depressive disorder; Medicine; Psychosis; Internal medicine; Adverse effect; Mood","score_opus":0.054905050638284165,"score_gpt":0.44423502764290745,"score_spread":0.3893299770046233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332272503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7711195,0.19538157,0.0021306318,0.0064658383,0.0006357817,0.00063428824,0.00031402838,0.00012551609,0.023192894],"genre_scores_gemma":[0.95341605,0.037230942,0.001848282,0.0018673902,0.0004992563,0.00022461766,0.00028544394,0.0000072664116,0.0046206564],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9998803,0.000043304986,0.000018315897,0.000007362813,0.000030004385,0.000020581514],"domain_scores_gemma":[0.9998679,0.000027919672,0.00006215666,0.0000058623527,0.000010519088,0.000025644465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002667158,0.00020250754,0.00022738871,0.00015533507,0.00018011626,0.0001380241,0.000104563616,0.00025205454,0.0028076102],"category_scores_gemma":[0.00042722255,0.000047545156,0.00023005312,0.00011504368,0.00013652208,0.00011402101,0.00016403991,0.0002678595,0.0005226446],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064292774,0.0008085663,0.04259507,0.0027344644,0.00023901995,0.019907497,0.0005852687,0.00023929503,0.07119903,0.0015278651,0.013769165,0.83996546],"study_design_scores_gemma":[0.008215757,0.036989637,0.52939755,0.002986128,0.0006893016,0.19965279,0.0012491117,0.0013112507,0.019401705,0.0030072103,0.19702917,0.00007038556],"about_ca_topic_score_codex":0.00016485278,"about_ca_topic_score_gemma":0.00076337415,"teacher_disagreement_score":0.0028076102,"about_ca_system_score_codex":0.0001261525,"about_ca_system_score_gemma":0.00021688583,"threshold_uncertainty_score":0.00939244},"labels":[],"label_agreement":null},{"id":"W2396912542","doi":"10.1097/wnf.0000000000000107","title":"Comparison Between Dysport and Prosigne in the Treatment of Cervical Dystonia","year":2015,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cervical dystonia; Dystonia; Medicine; Dermatology; Pediatrics; Psychiatry","score_opus":0.20953117186293277,"score_gpt":0.4772698150497375,"score_spread":0.26773864318680474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2396912542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99504554,0.0042569092,0.00009709926,0.000050941017,0.000021502728,0.00017005185,0.00002806242,0.000005495762,0.0003244427],"genre_scores_gemma":[0.9968706,0.0020318185,0.00048427025,0.00009073293,0.000057207737,0.00015950997,0.00007633815,0.0000015897131,0.0002279938],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9988299,0.0007070079,0.00014381994,0.00010562267,0.00015247686,0.00006107832],"domain_scores_gemma":[0.9987803,0.0004595403,0.0004467543,0.000060355273,0.000090506415,0.00016254901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015869613,0.0003656625,0.0010120147,0.00036974327,0.0001973001,0.00034053758,0.00036793316,0.00054346473,0.0014573747],"category_scores_gemma":[0.0016580826,0.00015939845,0.0005639193,0.0002505859,0.0005238236,0.00034290226,0.00027710342,0.00036385638,0.00009988668],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67071915,0.0163512,0.01927795,0.0037236505,0.003789944,0.00025916105,0.00038285143,0.0011455733,0.032343056,0.00038010723,0.00025062257,0.25137672],"study_design_scores_gemma":[0.112225845,0.8143617,0.062664434,0.0002118753,0.0019269735,0.00043590151,0.00016893075,0.00061140873,0.0050874646,0.00013064145,0.002141198,0.000033629083],"about_ca_topic_score_codex":0.00063846627,"about_ca_topic_score_gemma":0.001756136,"teacher_disagreement_score":0.0015869613,"about_ca_system_score_codex":0.00042769648,"about_ca_system_score_gemma":0.00044042087,"threshold_uncertainty_score":0.008392751},"labels":[],"label_agreement":null},{"id":"W2399313480","doi":"10.1097/wnf.0000000000000102","title":"Caffeine and Progression of Parkinson Disease","year":2015,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Coffee research and impacts","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Center for Research Resources; National Institute of Neurological Disorders and Stroke","keywords":"Caffeine; Medicine; Parkinson's disease; Disease; Neuroscience; Psychology; Internal medicine","score_opus":0.18888405364847727,"score_gpt":0.5239963377592634,"score_spread":0.3351122841107861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2399313480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96983016,0.026143417,0.00023368477,0.0002817462,0.000024882887,0.00004322144,0.0009851091,0.000035080255,0.0024228205],"genre_scores_gemma":[0.9955432,0.0028229994,0.00026485097,0.000056299752,0.000024275218,0.000012454444,0.00051153067,0.0000051515344,0.0007591839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99962246,0.000113926384,0.00003960275,0.00008193408,0.00010208284,0.00003996821],"domain_scores_gemma":[0.99816847,0.00020110089,0.0011565286,0.000057188445,0.0002486611,0.00016808842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067358295,0.00034279228,0.00034844095,0.00086449954,0.00042062215,0.00047513726,0.00018250594,0.0003846894,0.0016567957],"category_scores_gemma":[0.001953466,0.00014462954,0.00040419723,0.0006315034,0.00018597575,0.00020592983,0.0003153494,0.000401482,0.00019184846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007086486,0.00052397186,0.9301683,0.0005878798,0.0012443132,0.00031259243,0.00027356323,0.00037993697,0.007951799,0.00017607858,0.0011062735,0.050188847],"study_design_scores_gemma":[0.000029439947,0.0005020224,0.99727136,0.00005269955,0.00016664938,0.00021406122,0.000021144499,0.00011401833,0.00033674372,0.000080086385,0.0012052888,0.0000064474534],"about_ca_topic_score_codex":0.00618447,"about_ca_topic_score_gemma":0.0101712085,"teacher_disagreement_score":0.00618447,"about_ca_system_score_codex":0.00057608954,"about_ca_system_score_gemma":0.00039360992,"threshold_uncertainty_score":0.012296915},"labels":[],"label_agreement":null},{"id":"W2405021905","doi":"10.1097/wnf.0000000000000090","title":"Tolerability and Safety of Combined Glatiramer Acetate and N-Acetylcysteine in Relapsing-Remitting Multiple Sclerosis","year":2015,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Charles-Le Moyne; NeuroRx Research (Canada); Jewish General Hospital","funders":"","keywords":"Tolerability; Glatiramer acetate; Multiple sclerosis; Medicine; Experimental autoimmune encephalomyelitis; Neuroprotection; Pharmacology; Neurodegeneration; Internal medicine; Adverse effect; Immunology","score_opus":0.2073606310697216,"score_gpt":0.411588515682213,"score_spread":0.2042278846124914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2405021905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984964,0.00093175675,0.000091661765,0.00004120482,0.000009834674,0.000079054174,0.000070485046,0.000015784091,0.00026380506],"genre_scores_gemma":[0.9992575,0.00020847275,0.00014128495,0.000049715683,0.000027793925,0.000044608943,0.00009491956,0.0000026290415,0.00017311882],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99957377,0.00022245625,0.000038088314,0.00005022137,0.000068716785,0.000046685785],"domain_scores_gemma":[0.9995771,0.00009504361,0.00012065457,0.000040547566,0.000039217903,0.00012738584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075447717,0.00049276,0.0010283113,0.00023091542,0.00027971956,0.00026729875,0.00033735717,0.00051922095,0.0014820774],"category_scores_gemma":[0.0008433026,0.00018068201,0.0004555314,0.00020396594,0.00032501106,0.0003469743,0.00015725246,0.0007022069,0.0003470155],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.525321,0.030750372,0.039340016,0.0007703487,0.0019598766,0.00090180634,0.0004727771,0.0012818659,0.18305041,0.000061807325,0.000873415,0.21521638],"study_design_scores_gemma":[0.045416784,0.81232554,0.12090912,0.00004893558,0.0008844279,0.0008764961,0.00013863368,0.00087918586,0.016976144,0.00005506074,0.0014584945,0.000031244963],"about_ca_topic_score_codex":0.00057040976,"about_ca_topic_score_gemma":0.0012006274,"teacher_disagreement_score":0.0014820774,"about_ca_system_score_codex":0.00035769012,"about_ca_system_score_gemma":0.00031408202,"threshold_uncertainty_score":0.0049580336},"labels":[],"label_agreement":null},{"id":"W2802597050","doi":"10.1097/wnf.0000000000000275","title":"A Randomized Trial of Oral and Transdermal Rivastigmine for Postural Instability in Parkinson Disease Dementia","year":2018,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease and Spinal Disorders","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Interdisciplinary Research in Rehabilitation; Université de Montréal; Centre hospitalier universitaire de Québec; Université Laval; Children's Hospital of Eastern Ontario","funders":"","keywords":"Rivastigmine; Parkinson's disease; Transdermal; Dementia; Medicine; Postural instability; Randomized controlled trial; Disease; Physical medicine and rehabilitation; Psychology; Internal medicine; Pharmacology; Donepezil","score_opus":0.06762188235762388,"score_gpt":0.4176556982694887,"score_spread":0.3500338159118648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802597050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98740935,0.00412603,0.0006212329,0.0005840514,0.0009478463,0.0037516484,0.0005947807,0.00010929727,0.0018558328],"genre_scores_gemma":[0.98728883,0.0020343119,0.0012621185,0.00090218603,0.00069869077,0.0049380227,0.00054634304,0.000016630493,0.002312759],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989134,0.0005881199,0.00009883193,0.00017049824,0.00008229744,0.00014690733],"domain_scores_gemma":[0.99874735,0.00042229102,0.00031042314,0.00010532176,0.00008502358,0.0003296336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014832902,0.0014938804,0.00386557,0.00046159155,0.0004139926,0.0011183971,0.0008692565,0.0016343015,0.0063306526],"category_scores_gemma":[0.0024783127,0.00071961223,0.0015835117,0.0003775596,0.0011276073,0.001013558,0.000455579,0.0025122042,0.001078531],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9890205,0.0031308194,0.00018711457,0.00025906885,0.0004188944,0.000021752221,0.000019021089,0.00007885631,0.0007826571,0.000041797713,0.00014988008,0.005889647],"study_design_scores_gemma":[0.96589744,0.033066057,0.0004538529,0.000012092677,0.00014614534,0.000014594498,0.000009208235,0.000108969216,0.000098617165,0.00004204849,0.00014644336,0.0000046436207],"about_ca_topic_score_codex":0.0007461669,"about_ca_topic_score_gemma":0.0014973361,"teacher_disagreement_score":0.0063306526,"about_ca_system_score_codex":0.00066912756,"about_ca_system_score_gemma":0.0010709801,"threshold_uncertainty_score":0.021178126},"labels":[],"label_agreement":null},{"id":"W2809241434","doi":"10.1097/wnf.0000000000000285","title":"Postural Disorders and Antiparkinsonian Treatments in Parkinson Disease: An Exploratory Case-Control Study","year":2018,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease and Spinal Disorders","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Parkinson's disease; Movement disorders; Depression (economics); Levodopa; Rating scale; Logistic regression; Amantadine; Physical therapy; Disease; Psychology","score_opus":0.045309804874049044,"score_gpt":0.39931644791941845,"score_spread":0.3540066430453694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809241434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999054,0.00039657933,0.00018472047,0.00001376401,0.000006457735,0.00004797473,0.00004592508,0.0000033654844,0.00024716635],"genre_scores_gemma":[0.9992982,0.00015793958,0.00021575144,0.000025593677,0.000030051733,0.00003836929,0.00012286876,0.0000015821107,0.00010954437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986268,0.00037182047,0.00017157316,0.00046185055,0.00024336143,0.0001246752],"domain_scores_gemma":[0.99851793,0.00043893277,0.0004548718,0.00022701366,0.00016513186,0.00019625534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012991577,0.0006879872,0.0007109339,0.0016247869,0.0014960135,0.00069719274,0.00056204654,0.0009535899,0.002292245],"category_scores_gemma":[0.0026985789,0.00069722603,0.000570531,0.0009207171,0.0007774909,0.00057356525,0.0007385594,0.0004221262,0.00033322192],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005652448,0.0007134071,0.99138266,0.000048307968,0.00013930917,0.0033706487,0.000422054,0.000026178137,0.00092505146,0.00006570378,0.00009261796,0.0022488218],"study_design_scores_gemma":[0.0002383513,0.00381383,0.9638755,0.00003122091,0.00025442388,0.028962046,0.0011055265,0.00036076602,0.0004106642,0.00010260017,0.0008209451,0.000024173782],"about_ca_topic_score_codex":0.0015597125,"about_ca_topic_score_gemma":0.0015890236,"teacher_disagreement_score":0.002292245,"about_ca_system_score_codex":0.00031691574,"about_ca_system_score_gemma":0.0003761551,"threshold_uncertainty_score":0.0076683164},"labels":[],"label_agreement":null},{"id":"W2882844","doi":"","title":"Role of Remote Sensing in Disaster Management","year":2002,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Synthetic Aperture Radar (SAR) Applications and Techniques","field":"Engineering","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute for Catastrophic Loss Reduction","keywords":"Remote sensing; Emergency management; Computer science; Business; Computer security; Geography; Political science","score_opus":0.024849732616658262,"score_gpt":0.304537285211696,"score_spread":0.27968755259503775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2882844","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.044827286,0.43133765,0.2047075,0.046413515,0.004882999,0.0004015835,0.0015342415,0.0012349499,0.26466027],"genre_scores_gemma":[0.63287026,0.22227097,0.12163611,0.0036701579,0.0029565596,0.00014358804,0.00077067607,0.00016631758,0.015515363],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99811137,0.0010089471,0.00008135143,0.00021691108,0.0005010943,0.00008030564],"domain_scores_gemma":[0.99665797,0.0020767585,0.00028135855,0.00025692093,0.0006118649,0.00011514876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003049458,0.0006290331,0.0005534772,0.0020274576,0.0005896917,0.003315486,0.00087789644,0.0011750981,0.0036689774],"category_scores_gemma":[0.003488891,0.00021694518,0.0003277783,0.0026657614,0.0017934316,0.0029834546,0.0017245526,0.0013280015,0.0010352678],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000110804285,0.000116122435,0.011089213,0.0023141846,0.00013267128,0.00060703553,0.0010390558,0.021362882,0.0037900864,0.10802173,0.02948481,0.8219315],"study_design_scores_gemma":[0.000021135205,0.00040390677,0.019743199,0.0037348252,0.00011003417,0.0012880705,0.005574067,0.041523177,0.0037177198,0.17829356,0.74537545,0.0002148734],"about_ca_topic_score_codex":0.002943112,"about_ca_topic_score_gemma":0.0017324795,"teacher_disagreement_score":0.0036689774,"about_ca_system_score_codex":0.00084842223,"about_ca_system_score_gemma":0.0010625927,"threshold_uncertainty_score":0.016127288},"labels":[],"label_agreement":null},{"id":"W2920938584","doi":"10.1097/wnf.0000000000000326","title":"Real-World Experience With VMAT2 Inhibitors","year":2019,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Genetic Neurodegenerative Diseases","field":"Neuroscience","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dystonia Medical Research Foundation Canada; WiLAN (Canada)","funders":"","keywords":"Tetrabenazine; Tics; Medicine; Medical prescription; Dose; Internal medicine; Vesicular monoamine transporter; Pediatrics; Psychiatry; Monoamine neurotransmitter; Pharmacology; Dopamine","score_opus":0.06645725897481558,"score_gpt":0.40164267215679794,"score_spread":0.33518541318198236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920938584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97557133,0.013119878,0.000976833,0.0023838317,0.00008109418,0.000030809595,0.00033997238,0.00004260719,0.007453705],"genre_scores_gemma":[0.991723,0.0058170697,0.00063665374,0.00085939525,0.000108618,0.000014221897,0.00022584994,0.000020519003,0.00059452996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980551,0.0008504787,0.00024860722,0.0002274325,0.0004163975,0.00020187063],"domain_scores_gemma":[0.9916427,0.001963471,0.0045563974,0.00018989929,0.00066286675,0.0009847343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012507233,0.00015646858,0.00020105668,0.0004156267,0.00058539095,0.0010432508,0.0005038816,0.00046314142,0.0025581184],"category_scores_gemma":[0.010387941,0.00017547398,0.000304622,0.00060954655,0.0005795139,0.0010766551,0.0007696434,0.00065171963,0.00039221055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051020924,0.0004798758,0.85539496,0.00089942047,0.0002790612,0.011442988,0.0117380805,0.0010835713,0.0020445304,0.00091426104,0.009576487,0.10563656],"study_design_scores_gemma":[0.00014066251,0.002744937,0.65120745,0.0012241391,0.00037657263,0.19688371,0.02441516,0.0026773836,0.003411554,0.00066764053,0.116068654,0.0001821861],"about_ca_topic_score_codex":0.002587684,"about_ca_topic_score_gemma":0.0042541143,"teacher_disagreement_score":0.002587684,"about_ca_system_score_codex":0.00088395254,"about_ca_system_score_gemma":0.0007857865,"threshold_uncertainty_score":0.008557737},"labels":[],"label_agreement":null},{"id":"W2943068831","doi":"10.1097/wnf.0000000000000344","title":"Curcumin as Add-On to Antipsychotic Treatment in Patients With Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study","year":2019,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Curcumin's Biomedical Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Curcumin; Schizophrenia (object-oriented programming); Placebo; Antipsychotic; Positive and Negative Syndrome Scale; Medicine; Internal medicine; Adverse effect; Randomized controlled trial; Depression (economics); Psychiatry; Clinical trial; Psychology; Psychosis; Pharmacology","score_opus":0.02028843139327818,"score_gpt":0.3621573988056611,"score_spread":0.34186896741238293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943068831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742964,0.014948037,0.0006193975,0.00046405333,0.0008649214,0.0071183415,0.0007242647,0.00013010348,0.00083449896],"genre_scores_gemma":[0.9729006,0.011481983,0.0026927497,0.001159303,0.0010882806,0.007880145,0.0006115976,0.000022514283,0.0021629082],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99914,0.00035847002,0.000119189484,0.0001683599,0.00010986409,0.000104056526],"domain_scores_gemma":[0.9987663,0.00028159955,0.00033202695,0.000103033075,0.00017802756,0.0003389951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019644306,0.001523758,0.0050608627,0.000903377,0.00065382704,0.00079446874,0.0008450888,0.0020961482,0.004987729],"category_scores_gemma":[0.0017456979,0.00088162464,0.0019545485,0.00066970143,0.0014044845,0.001012342,0.00051013316,0.0017278065,0.0005281324],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96615076,0.013433413,0.0006338706,0.002105082,0.0012290527,0.00005281018,0.00005127254,0.00008432438,0.003684759,0.000027254931,0.00032800392,0.012219387],"study_design_scores_gemma":[0.9021613,0.09317745,0.002573184,0.000063378786,0.00096477935,0.000027264336,0.000024750092,0.00012991962,0.00036724666,0.000034394456,0.00045622475,0.000020037767],"about_ca_topic_score_codex":0.0009790009,"about_ca_topic_score_gemma":0.0026538696,"teacher_disagreement_score":0.0050608627,"about_ca_system_score_codex":0.0006328898,"about_ca_system_score_gemma":0.0015672402,"threshold_uncertainty_score":0.016685545},"labels":[],"label_agreement":null},{"id":"W3013161772","doi":"10.1097/wnf.0000000000000384","title":"Effect of Antidepressants on Psychotic Symptoms in Parkinson Disease: A Review of Case Reports and Case Series","year":2020,"lang":"en","type":"review","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; Montreal Neurological Institute and Hospital; McGill University Health Centre; Université de Montréal","funders":"","keywords":"Venlafaxine; Mirtazapine; Mianserin; Parkinsonism; Psychosis; Psychiatry; Escitalopram; Randomized controlled trial; Medicine; Antipsychotic; Citalopram; Ziprasidone; Anticholinergic; Psychology; Antidepressant; Schizophrenia (object-oriented programming); Disease; Internal medicine; Anxiety","score_opus":0.05376582530136106,"score_gpt":0.4460727770714156,"score_spread":0.3923069517700546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013161772","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00063655025,0.998718,0.000075066855,0.00007932655,0.000058010482,0.000010451865,0.000026581865,0.000004703012,0.0003912815],"genre_scores_gemma":[0.00931799,0.98974544,0.00027892203,0.00021752073,0.0001622542,0.000016887921,0.00006348841,0.0000029869025,0.00019457807],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99929595,0.000104885614,0.00033025432,0.00009921624,0.00013026861,0.00003933203],"domain_scores_gemma":[0.9983919,0.00091620506,0.00042359394,0.00006363181,0.00015634754,0.0000482799],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006344319,0.0011637211,0.0017430334,0.0052400297,0.000503678,0.0008432612,0.0011412905,0.001125742,0.0029790406],"category_scores_gemma":[0.0026041165,0.00039463447,0.0012285308,0.005335165,0.00064281106,0.0011557488,0.00063034013,0.0007230293,0.0007010879],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027538335,0.00012435048,0.0048816334,0.15482552,0.0012729688,0.037596162,0.00075166643,0.00042408405,0.0021816376,0.0011236503,0.019840881,0.77670205],"study_design_scores_gemma":[0.00016112614,0.00048932753,0.022039719,0.115180135,0.0070199966,0.4680059,0.0012939165,0.00022495213,0.0019904878,0.0020354379,0.3814083,0.00015072184],"about_ca_topic_score_codex":0.0014582812,"about_ca_topic_score_gemma":0.0029594514,"teacher_disagreement_score":0.0052400297,"about_ca_system_score_codex":0.0005689969,"about_ca_system_score_gemma":0.0012111074,"threshold_uncertainty_score":0.009965897},"labels":[],"label_agreement":null},{"id":"W3022758378","doi":"10.1097/wnf.0000000000000390","title":"Successful Treatment With Lithium in a Refractory Patient With Periodic Catatonic Features: A Case Report","year":2020,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Electroconvulsive Therapy Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Catatonia; Electroconvulsive therapy; Lithium (medication); Refractory (planetary science); Benzodiazepine; Medicine; Antipsychotic; Atypical antipsychotic; Psychiatry; Pediatrics; Anesthesia; Schizophrenia (object-oriented programming); Internal medicine","score_opus":0.040125661092529206,"score_gpt":0.36987657790497225,"score_spread":0.32975091681244306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022758378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9650575,0.008588122,0.0033166762,0.0070522567,0.0006441227,0.0002555286,0.00017454076,0.00028616155,0.014625037],"genre_scores_gemma":[0.99135196,0.0019887174,0.0013155276,0.0023034688,0.0010008995,0.000050647104,0.00008364913,0.00003330536,0.0018718658],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9995435,0.000088603956,0.00006407242,0.00008314853,0.00007536068,0.00014531845],"domain_scores_gemma":[0.99909425,0.00028121314,0.0001744225,0.000094134986,0.00005068863,0.00030533754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002970729,0.0014767958,0.0010262448,0.0011203913,0.0023180312,0.001172245,0.0010835269,0.006545411,0.0012760077],"category_scores_gemma":[0.00253905,0.0007174111,0.0012956687,0.0007284748,0.0013093182,0.001053893,0.0009895816,0.0024482068,0.00081418233],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035498368,0.00006899425,0.002874303,0.00002758711,0.000012112327,0.9942169,0.00014310729,0.00005120655,0.0005653014,0.000081757236,0.00030365985,0.0016194581],"study_design_scores_gemma":[0.000029975881,0.00013445163,0.002364922,0.000015175731,0.000019250703,0.99608886,0.00006681189,0.00021262903,0.0003929676,0.000069215195,0.00059311255,0.00001267501],"about_ca_topic_score_codex":0.0015841457,"about_ca_topic_score_gemma":0.0023996981,"teacher_disagreement_score":0.006545411,"about_ca_system_score_codex":0.00090976944,"about_ca_system_score_gemma":0.0009863488,"threshold_uncertainty_score":0.0066009164},"labels":[],"label_agreement":null},{"id":"W3126282994","doi":"10.1097/wnf.0000000000000437","title":"Oral Levodopa Formulation Does Not Affect Progression of Parkinson Disease","year":2021,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Neurological Disorders and Stroke","keywords":"Levodopa; Carbidopa; Parkinson's disease; Dyskinesia; Psychology; Rating scale; Medicine; Internal medicine; Disease; Physical therapy; Developmental psychology","score_opus":0.06823438487166537,"score_gpt":0.43020540234244414,"score_spread":0.36197101747077876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126282994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996434,0.002054754,0.00030571118,0.000051157083,0.000011857586,0.000041689294,0.00020113586,0.00003481385,0.00086491165],"genre_scores_gemma":[0.99910337,0.00022068288,0.00017919947,0.000030588784,0.00000486352,0.000009842774,0.00010854712,0.000003947224,0.00033894542],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99950075,0.00020251577,0.0000354965,0.00008468489,0.00014483064,0.000031656207],"domain_scores_gemma":[0.9983979,0.00065723254,0.0006126201,0.000098226854,0.000103938684,0.0001301575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008782867,0.00018458557,0.0004913871,0.00011947547,0.00011050923,0.00040694512,0.00018772134,0.0003305272,0.001583103],"category_scores_gemma":[0.003192342,0.00011999726,0.0004596289,0.00011963439,0.00018954293,0.00031295008,0.00011597584,0.0003971794,0.00017644138],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17435183,0.007885427,0.32219827,0.0015063845,0.0046095736,0.0006324913,0.00045020267,0.0023264796,0.107742205,0.00022308815,0.0012333319,0.37684068],"study_design_scores_gemma":[0.003457921,0.11517676,0.85434294,0.0001508575,0.0020448982,0.0015232115,0.000112514885,0.0051445146,0.014541081,0.00020529398,0.0032677832,0.000032122294],"about_ca_topic_score_codex":0.0006992875,"about_ca_topic_score_gemma":0.0012029707,"teacher_disagreement_score":0.001583103,"about_ca_system_score_codex":0.00025478745,"about_ca_system_score_gemma":0.00022578178,"threshold_uncertainty_score":0.005295992},"labels":[],"label_agreement":null},{"id":"W3211406171","doi":"10.1097/wnf.0000000000000483","title":"Antidepressants Effects on Pain in Parkinson Disease: A Systematic Review","year":2021,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotchkiss Brain Institute; Women and Children’s Health Research Institute; University of Alberta; University of Calgary","funders":"","keywords":"Placebo; Placebo response; Antidepressant; Prospective cohort study; Depression (economics)","score_opus":0.037785309027738384,"score_gpt":0.3841313402087246,"score_spread":0.34634603118098617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211406171","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00093874143,0.9983846,0.00004218396,0.00010844504,0.00006224209,0.00012601854,0.0001651985,0.000003670041,0.00016891166],"genre_scores_gemma":[0.013527569,0.9854441,0.00024030624,0.00029159838,0.00007134819,0.00020395266,0.0001227054,0.0000019217018,0.00009648348],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9973794,0.00082223985,0.0009682769,0.00021420082,0.00050513854,0.0001106186],"domain_scores_gemma":[0.9900739,0.0068680905,0.0020902182,0.00009786341,0.0007397069,0.00013020233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029850677,0.0011973258,0.0065654498,0.00521965,0.00050880766,0.0018375462,0.0011464347,0.001504357,0.004236929],"category_scores_gemma":[0.013701136,0.00069840805,0.0060079703,0.005730543,0.00054305414,0.001160899,0.00094042264,0.0007580825,0.0002647283],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025354428,0.000015261861,0.00055272004,0.96410495,0.008344101,0.00011001962,0.00008954116,0.00007247137,0.00013867824,0.0000954943,0.0009865444,0.025236562],"study_design_scores_gemma":[0.0005558526,0.00040769775,0.006942796,0.8542254,0.12022609,0.00066706573,0.00020849044,0.00010296919,0.00022359466,0.00020396536,0.01620148,0.000034622542],"about_ca_topic_score_codex":0.0062341,"about_ca_topic_score_gemma":0.021582408,"teacher_disagreement_score":0.0065654498,"about_ca_system_score_codex":0.0021342104,"about_ca_system_score_gemma":0.005729081,"threshold_uncertainty_score":0.015786767},"labels":[],"label_agreement":null},{"id":"W4214529031","doi":"10.1097/wnf.0000000000000494","title":"Clinical Management of Sleep and Sleep Disorders With Cannabis and Cannabinoids: Implications to Practicing Psychiatrists","year":2022,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Muscular Dystrophy Canada","funders":"","keywords":"Cannabidiol; Cannabis; Sleep (system call); Effects of cannabis; Zolpidem; Abstinence; Obstructive sleep apnea; Hypnotic; Endocannabinoid system","score_opus":0.02964046852465191,"score_gpt":0.4123524850349535,"score_spread":0.38271201651030157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214529031","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.057531733,0.30763498,0.0047882684,0.56615007,0.0056744427,0.00034101398,0.000292374,0.00026879788,0.057318237],"genre_scores_gemma":[0.48415473,0.37841997,0.021710943,0.081461586,0.01773391,0.000557185,0.00030196304,0.00006696542,0.015592787],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993794,0.0002294668,0.00008365892,0.00004234843,0.0001929161,0.00007220899],"domain_scores_gemma":[0.99802303,0.000512256,0.00032048213,0.000029635781,0.0005458358,0.00056872814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086102984,0.0004984135,0.00064082065,0.0008757455,0.0018701908,0.0011547117,0.00079284725,0.0026447552,0.0050830985],"category_scores_gemma":[0.0038819571,0.0002609745,0.00034761117,0.0005306476,0.00088169187,0.0016871964,0.0012959057,0.002675042,0.0012862001],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003424027,0.0012771414,0.060360506,0.00307438,0.00009878611,0.048062313,0.002981524,0.0010097318,0.002753198,0.0035354123,0.22987269,0.6466319],"study_design_scores_gemma":[0.0006635215,0.0018659097,0.25793472,0.028609375,0.00029188907,0.22685663,0.050965153,0.005847985,0.0015217796,0.035963267,0.388951,0.00052880956],"about_ca_topic_score_codex":0.0055623422,"about_ca_topic_score_gemma":0.01614101,"teacher_disagreement_score":0.0055623422,"about_ca_system_score_codex":0.0016495797,"about_ca_system_score_gemma":0.0035724281,"threshold_uncertainty_score":0.01700461},"labels":[],"label_agreement":null},{"id":"W4248937293","doi":"10.1097/00002826-200001000-00007","title":"A Randomized Controlled Trial Comparing Pramipexole with Levodopa in Early Parkinson's Disease: Design and Methods of the CALM-PD Study","year":2000,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Center for Research Resources","keywords":"Pramipexole; Levodopa; Tolerability; Parkinson's disease; Medicine; Randomized controlled trial; Entacapone; Placebo; Dopaminergic; Clinical trial; Psychology; Internal medicine; Disease; Adverse effect; Dopamine","score_opus":0.06708977375762877,"score_gpt":0.4175193602424132,"score_spread":0.35042958648478445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248937293","genre_codex":"protocol","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.43485835,0.011239674,0.015689822,0.0033541727,0.0071321107,0.5124976,0.0046001053,0.0006614514,0.009966753],"genre_scores_gemma":[0.4112511,0.0040216246,0.030724725,0.0039661797,0.0025485428,0.5357186,0.0021039548,0.000097264725,0.009567924],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.97641265,0.018699592,0.0011942401,0.0016476474,0.0010359858,0.0010099072],"domain_scores_gemma":[0.9885034,0.0066758026,0.0016822665,0.0010359968,0.0008401015,0.0012624046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022605894,0.004720983,0.008305431,0.001464527,0.00097174227,0.0022648415,0.0016504398,0.004855968,0.013053487],"category_scores_gemma":[0.024657246,0.0017889896,0.0046704994,0.0013623474,0.0025830236,0.0020805825,0.0013005016,0.0038096537,0.0021632873],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98609734,0.004262425,0.0004157595,0.00073411287,0.0015932538,0.000032645457,0.00004911036,0.00035621092,0.0003308939,0.0006092165,0.000429228,0.005089687],"study_design_scores_gemma":[0.9751956,0.022161525,0.0003036947,0.00003244019,0.00069985003,0.000007923872,0.000009913382,0.00047137923,0.00007282064,0.0003122715,0.0007198352,0.000012799932],"about_ca_topic_score_codex":0.0011736439,"about_ca_topic_score_gemma":0.0017007509,"teacher_disagreement_score":0.022605894,"about_ca_system_score_codex":0.0013248464,"about_ca_system_score_gemma":0.0040854127,"threshold_uncertainty_score":0.11955285},"labels":[],"label_agreement":null},{"id":"W4280488756","doi":"10.1097/wnf.0000000000000501","title":"The Effect of Rotigotine on Cognitive Function, Daytime Sleepiness, and Sleep Problems in Parkinson Disease: An Open-Label Pilot Study","year":2022,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Montreal Cognitive Assessment; Epworth Sleepiness Scale; Rotigotine; Parkinson's disease; Rating scale; Excessive daytime sleepiness; Medicine; Mini–Mental State Examination; Cognition; Psychology; Internal medicine; Polysomnography; Physical therapy; Sleep disorder; Cognitive impairment; Disease; Psychiatry","score_opus":0.07015290439550931,"score_gpt":0.3944054171373183,"score_spread":0.324252512741809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280488756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99721634,0.0007679621,0.00037062206,0.00006147749,0.00005265138,0.0009997615,0.00019718404,0.000036618454,0.00029742994],"genre_scores_gemma":[0.99426585,0.0007943607,0.0015030892,0.000210529,0.00021898694,0.001977043,0.00041239022,0.000015163682,0.0006025832],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99920124,0.00038480115,0.000069787544,0.00012867563,0.00009670283,0.00011875077],"domain_scores_gemma":[0.9982426,0.00055273564,0.00034001455,0.00021549537,0.00014011949,0.0005091583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024202643,0.0016343747,0.0023304073,0.0005370191,0.0005499696,0.0006374412,0.0010703799,0.0013239665,0.0028955003],"category_scores_gemma":[0.0015529845,0.0005761105,0.0014134947,0.0004350332,0.0018962945,0.0012810682,0.00047143697,0.0020857598,0.0005713514],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65795827,0.20701127,0.0047210287,0.0010570236,0.00071908353,0.0002882379,0.00045930583,0.00086071074,0.06820982,0.00007841051,0.000654566,0.05798225],"study_design_scores_gemma":[0.14770961,0.83749545,0.010579434,0.000019012321,0.00018854123,0.000117439275,0.000053155192,0.0005542352,0.0028496464,0.000039600036,0.00037193854,0.00002201956],"about_ca_topic_score_codex":0.00061257154,"about_ca_topic_score_gemma":0.0011474268,"teacher_disagreement_score":0.0028955003,"about_ca_system_score_codex":0.00039810754,"about_ca_system_score_gemma":0.001025824,"threshold_uncertainty_score":0.01279974},"labels":[],"label_agreement":null},{"id":"W4309181475","doi":"10.1097/wnf.0000000000000528","title":"Protective Effects of Ursodeoxycholic Acid Against Oxidative Stress and Neuroinflammation Through Mitogen-Activated Protein Kinases Pathway in MPTP-Induced Parkinson Disease","year":2022,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"MPTP; Ursodeoxycholic acid; Oxidative stress; Pharmacology; Neuroinflammation; Superoxide dismutase; Chemistry; Endocrinology; p38 mitogen-activated protein kinases; Internal medicine; Kinase; Medicine; Dopamine; Protein kinase A; Biochemistry; Inflammation; Dopaminergic","score_opus":0.03706120007032836,"score_gpt":0.3400274841243841,"score_spread":0.30296628405405573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309181475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9613113,0.03476741,0.0019545872,0.00033183405,0.000113540285,0.00006324304,0.0002584679,0.00010399913,0.0010955868],"genre_scores_gemma":[0.98463446,0.012039402,0.0018193435,0.00013335129,0.000043895445,0.00008276662,0.00027997236,0.00000993307,0.00095685467],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993324,0.000014206351,0.000010879887,0.000012288969,0.0000131150155,0.000016247232],"domain_scores_gemma":[0.99993014,0.0000045067472,0.000022922515,0.000005462622,0.000014226508,0.000022857026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001308167,0.00041936216,0.000530728,0.00045671887,0.00021755853,0.00018552216,0.00019916472,0.0003332022,0.0007129214],"category_scores_gemma":[0.00014765038,0.0001305499,0.00033190043,0.00022583046,0.00026055955,0.0003750415,0.00022123576,0.0005063547,0.0001159241],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003959485,0.00053194206,0.0015827771,0.0008826822,0.000116876574,0.00032882133,0.000080708116,0.00021932527,0.97352594,0.00018939901,0.0002444705,0.018337617],"study_design_scores_gemma":[0.0007901881,0.0077410047,0.033414803,0.00017738239,0.00045722027,0.0011215628,0.00021389566,0.001832869,0.9416443,0.00053312955,0.012040052,0.00003359281],"about_ca_topic_score_codex":0.0002675805,"about_ca_topic_score_gemma":0.0004789337,"teacher_disagreement_score":0.0007129214,"about_ca_system_score_codex":0.000120767276,"about_ca_system_score_gemma":0.00024858868,"threshold_uncertainty_score":0.0023850203},"labels":[],"label_agreement":null},{"id":"W4323809901","doi":"10.1097/wnf.0000000000000548","title":"The Downside of Botulinum Injections for Anterocollis: A Case Series and a Review of the Literature","year":2023,"lang":"en","type":"review","venue":"Clinical Neuropharmacology","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"","keywords":"Medicine; Botulinum toxin; Clinical Global Impression; Weakness; Head and neck; Surgery; Abnormality; Physical therapy","score_opus":0.1151259745079861,"score_gpt":0.47201173835881644,"score_spread":0.3568857638508303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323809901","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38699016,0.5845681,0.0066813356,0.0027385415,0.001700541,0.0002542543,0.00029663462,0.00042120536,0.016349195],"genre_scores_gemma":[0.8302169,0.159269,0.0026530337,0.0018671552,0.003090931,0.000092028524,0.00030256668,0.000069949936,0.00243842],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9989048,0.00012965381,0.0003460727,0.00020195254,0.0002401056,0.00017741816],"domain_scores_gemma":[0.99817336,0.0006263797,0.0007561366,0.00011611567,0.00013940339,0.00018853814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004920435,0.0019412532,0.0012131822,0.0047651352,0.0013998275,0.0016723234,0.0013181122,0.0029331285,0.002189766],"category_scores_gemma":[0.0025949946,0.00068785343,0.0010775257,0.004341984,0.0013928091,0.0017774437,0.0009977758,0.0012995995,0.0012998433],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045192446,0.000071117836,0.020429328,0.0012482469,0.000085609514,0.9473545,0.0004805832,0.00013424974,0.0011094136,0.00019770976,0.0017984295,0.02704563],"study_design_scores_gemma":[0.0000049398436,0.000030090543,0.004360285,0.00028797262,0.000056090146,0.9919333,0.00021597731,0.00006192441,0.00021367517,0.00006971777,0.002754893,0.000011261227],"about_ca_topic_score_codex":0.00093135465,"about_ca_topic_score_gemma":0.00129906,"teacher_disagreement_score":0.0047651352,"about_ca_system_score_codex":0.00066059566,"about_ca_system_score_gemma":0.0007839925,"threshold_uncertainty_score":0.0073254704},"labels":[],"label_agreement":null},{"id":"W4381192770","doi":"10.1097/wnf.0000000000000557","title":"Botulinum Toxins and Zinc: From Theory to Practice—A Systematic Review","year":2023,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Botulinum toxin; Botulinum neurotoxin; Neurotoxin; Medicine; Longevity; Clinical trial; Randomized controlled trial; Meta-analysis; Zinc; Intensive care medicine; Internal medicine; Surgery; Toxin; Gerontology; Biology; Chemistry; Microbiology","score_opus":0.04423927413122207,"score_gpt":0.4346653475371222,"score_spread":0.39042607340590013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381192770","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011958043,0.99732155,0.00015144738,0.00059157785,0.000110899906,0.00026287948,0.00016746663,0.000004590063,0.00019391911],"genre_scores_gemma":[0.031703603,0.96523404,0.0010632534,0.00096693187,0.0001279886,0.00064331223,0.00016919119,0.000004247345,0.0000874281],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9858212,0.0057227914,0.00493971,0.00093138084,0.0022214942,0.0003634924],"domain_scores_gemma":[0.9361915,0.048483588,0.010230382,0.00067373837,0.003919717,0.0005011262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014532232,0.0015607048,0.008553861,0.017758701,0.0007058837,0.0036352216,0.0021667876,0.0023228177,0.003892633],"category_scores_gemma":[0.063727796,0.001226243,0.0061379173,0.015033984,0.0013647999,0.0036527314,0.0020607656,0.0013115567,0.00028640154],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023396396,0.00002427497,0.0018735082,0.9510928,0.010781836,0.00015550322,0.00025349384,0.00012604316,0.00013724224,0.00036967776,0.0013180036,0.03363371],"study_design_scores_gemma":[0.00028640247,0.000167407,0.0037882775,0.93099743,0.05566763,0.00041874245,0.00042406208,0.00015582707,0.00010406141,0.0005238775,0.0074354587,0.00003088068],"about_ca_topic_score_codex":0.0076314695,"about_ca_topic_score_gemma":0.021110738,"teacher_disagreement_score":0.017758701,"about_ca_system_score_codex":0.005886139,"about_ca_system_score_gemma":0.016422631,"threshold_uncertainty_score":0.076854765},"labels":[],"label_agreement":null},{"id":"W4387664863","doi":"10.1097/wnf.0000000000000574","title":"An Examination of the Relationship Between Exposure to Bisphenol A and Attention-Deficit/Hyperactivity Disorder in Children and Adolescents","year":2023,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Effects and risks of endocrine disrupting chemicals","field":"Environmental Science","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child, Adolescent and Family Mental Health","funders":"","keywords":"CBCL; Attention deficit hyperactivity disorder; Schedule for Affective Disorders and Schizophrenia; Child Behavior Checklist; Etiology; Attention deficit; Psychology; Schizophrenia (object-oriented programming); Psychiatry; Clinical psychology; Medicine; Pediatrics","score_opus":0.029229464312136414,"score_gpt":0.3984036566485896,"score_spread":0.3691741923364532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387664863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99870217,0.00033173343,0.00004416886,0.000053541764,0.0000057924562,0.000010801751,0.000270856,0.0000027903202,0.0005781113],"genre_scores_gemma":[0.99913234,0.000246547,0.00010739793,0.000025540305,0.0000075543808,0.000013301664,0.00026710433,0.000001240007,0.00019900533],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99963605,0.000085754255,0.000046894547,0.000069644746,0.00011327315,0.0000482879],"domain_scores_gemma":[0.9982668,0.0003739104,0.00084388716,0.000035851983,0.00024520018,0.00023444359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059413613,0.00022140435,0.00021033824,0.0012175675,0.0002918989,0.00034538243,0.0002625578,0.00041833843,0.0016546469],"category_scores_gemma":[0.0020282827,0.00019006939,0.00031283437,0.0008297557,0.0002006105,0.00028544036,0.00027423652,0.0004990984,0.00017273157],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021069516,0.00003459131,0.99895895,0.000008197482,0.000021785674,0.00007249553,0.000052796782,0.000005442358,0.00015022399,0.0000062282916,0.000031772237,0.00063650834],"study_design_scores_gemma":[8.5659076e-7,0.000041346324,0.9995814,0.0000026498328,0.000009442888,0.00017340797,0.00006813399,0.000013917856,0.00003727419,0.0000026776493,0.000068367466,4.977782e-7],"about_ca_topic_score_codex":0.00768903,"about_ca_topic_score_gemma":0.007987636,"teacher_disagreement_score":0.00768903,"about_ca_system_score_codex":0.00029101,"about_ca_system_score_gemma":0.00042545894,"threshold_uncertainty_score":0.015288532},"labels":[],"label_agreement":null},{"id":"W4390322720","doi":"10.1097/wnf.0000000000000580","title":"Effect of Levodopa on Heat Hypersensitivity and Complex Motor Parkinsonism","year":2023,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Health; Royal University Hospital; Saskatchewan Health Authority","funders":"","keywords":"Parkinsonism; Levodopa; Medicine; Asymptomatic; Atrophy; Orthostatic intolerance; Pediatrics; Movement disorders; Parkinson's disease; Physical therapy; Physical medicine and rehabilitation; Psychology; Orthostatic vital signs; Disease; Surgery; Internal medicine; Blood pressure","score_opus":0.07187846848099394,"score_gpt":0.4133951304737717,"score_spread":0.34151666199277775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390322720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844565,0.0068032024,0.00042300677,0.00044403484,0.00005481739,0.000032162083,0.00003402274,0.00003911369,0.0077132923],"genre_scores_gemma":[0.9987306,0.0004609876,0.000107433196,0.00018383027,0.000057248377,0.0000036029821,0.000021589627,0.0000025152438,0.00043220515],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.99987876,0.000028765211,0.00002123481,0.00002212204,0.000015981206,0.000033193],"domain_scores_gemma":[0.99961436,0.00015551966,0.00009301784,0.00002620733,0.000028991997,0.00008186601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018346313,0.00034010835,0.0003132704,0.00031320172,0.00033852604,0.0003114004,0.0001963387,0.00068151497,0.0012335894],"category_scores_gemma":[0.0008737306,0.000118517,0.00032968406,0.00012919806,0.00030060316,0.0002448173,0.00023836415,0.0004594688,0.00021609402],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030877,0.0004674161,0.11542385,0.00027675653,0.00016237832,0.81084985,0.00021256087,0.0003026437,0.018779168,0.00023626536,0.0007792795,0.049422167],"study_design_scores_gemma":[0.00025431914,0.0034890154,0.2034321,0.00009890272,0.00021456502,0.77725136,0.00025045415,0.001668931,0.007009074,0.00033409146,0.00596983,0.000027342532],"about_ca_topic_score_codex":0.0008742857,"about_ca_topic_score_gemma":0.0016245354,"teacher_disagreement_score":0.0012335894,"about_ca_system_score_codex":0.00039839096,"about_ca_system_score_gemma":0.00016359476,"threshold_uncertainty_score":0.0041267276},"labels":[],"label_agreement":null},{"id":"W4392691518","doi":"10.1097/wnf.0000000000000582","title":"Provider Experience With the Use of Ketamine for Refractory Status Epilepticus","year":2024,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ketamine; Midazolam; Propofol; Medicine; Status epilepticus; Neurointensive care; Anesthesia; Anesthetic; Epilepsy; Pharmacy; Intensive care medicine; Psychiatry; Nursing; Sedation","score_opus":0.18340622952259536,"score_gpt":0.46462725956431017,"score_spread":0.28122103004171484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392691518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953564,0.0008152021,0.00020937459,0.0015774196,0.00002636345,0.00002074895,0.00009564071,0.0000053921867,0.0018934216],"genre_scores_gemma":[0.99809486,0.000959564,0.0002839091,0.00033845252,0.000016056421,0.000012807035,0.000055310324,0.0000027288875,0.00023625992],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9978638,0.0012277392,0.00024707417,0.00008857654,0.0003945957,0.00017824843],"domain_scores_gemma":[0.98850983,0.0048100897,0.0043971697,0.00014115321,0.001079152,0.0010626324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00254023,0.00007850741,0.00012473612,0.0002860427,0.00039016287,0.00043370487,0.00019494952,0.0003190095,0.0032409502],"category_scores_gemma":[0.015033653,0.00016782804,0.0002124907,0.0003354,0.00037444028,0.00061275956,0.00046878407,0.00044643154,0.00020351505],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016493665,0.00026539186,0.95458573,0.00039423155,0.00008044045,0.001106099,0.010707329,0.00020641457,0.00062192976,0.00015806986,0.0022554111,0.029453948],"study_design_scores_gemma":[0.00004587024,0.0011661898,0.9289714,0.00083855353,0.00010159526,0.0093342,0.04653744,0.0011829081,0.00054133346,0.00015969388,0.01107809,0.000042734857],"about_ca_topic_score_codex":0.008275236,"about_ca_topic_score_gemma":0.0088355,"teacher_disagreement_score":0.008275236,"about_ca_system_score_codex":0.00074378116,"about_ca_system_score_gemma":0.0013387341,"threshold_uncertainty_score":0.01645416},"labels":[],"label_agreement":null},{"id":"W4413413666","doi":"10.1097/wnf.0000000000000651","title":"Assessing the Efficacy of Cognitive Enhancers in Electroconvulsive Therapy: A Randomized Controlled Trial of Rivastigmine and Memantine","year":2025,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Electroconvulsive Therapy Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Rivastigmine; Memantine; Electroconvulsive therapy; Montreal Cognitive Assessment; Cognition; Placebo; Randomized controlled trial; Medicine; Psychology; Effects of sleep deprivation on cognitive performance; Anesthesia; Internal medicine; Psychiatry; Donepezil; Dementia; Cognitive impairment","score_opus":0.03474986360129584,"score_gpt":0.4526716213914023,"score_spread":0.4179217577901065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413413666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98226446,0.007410477,0.0008848931,0.0007266102,0.0008142174,0.0057752323,0.00062451133,0.00014272385,0.0013570102],"genre_scores_gemma":[0.983696,0.0032369376,0.002291968,0.000736187,0.000644815,0.0073573217,0.00043517232,0.000028470247,0.0015731615],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99786025,0.0013030253,0.00024480387,0.00028315428,0.00016778529,0.0001408696],"domain_scores_gemma":[0.9980433,0.00071590353,0.0006276916,0.0001479924,0.00014143731,0.00032354458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003215891,0.001504362,0.0034603293,0.0005180558,0.0003993246,0.0012226391,0.0011467842,0.0018548595,0.004656219],"category_scores_gemma":[0.0042132707,0.0006854205,0.0018919206,0.00050655287,0.0011042462,0.0011274139,0.0003756013,0.0021930032,0.0006299092],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9854543,0.0040219757,0.00024240631,0.0005231215,0.0010042137,0.000015286048,0.000022994966,0.00010049709,0.0012170342,0.00004019349,0.00018351719,0.0071745096],"study_design_scores_gemma":[0.9645516,0.033819135,0.00064763374,0.00002355054,0.00038918623,0.000010610001,0.000008239784,0.0001918911,0.00016648702,0.00003465355,0.00015020766,0.000006830206],"about_ca_topic_score_codex":0.0008430407,"about_ca_topic_score_gemma":0.0018914649,"teacher_disagreement_score":0.004656219,"about_ca_system_score_codex":0.0008574974,"about_ca_system_score_gemma":0.0013135893,"threshold_uncertainty_score":0.01700747},"labels":[],"label_agreement":null},{"id":"W4417049185","doi":"10.1097/wnf.0000000000000665","title":"Amitriptyline for Refractory Idiopathic Intractable Hiccups: A Case Report","year":2025,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Pathogenesis and Treatment of Hiccups","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Government of New Brunswick","funders":"","keywords":"Amitriptyline; Refractory (planetary science); Intractable epilepsy; Psychogenic disease; Gabapentin; Mood","score_opus":0.07417162951320497,"score_gpt":0.4633633643222183,"score_spread":0.38919173480901337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417049185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5747465,0.3855223,0.0053870636,0.007911299,0.0010193911,0.00049827516,0.0007335109,0.00021165678,0.023969999],"genre_scores_gemma":[0.91342676,0.07488971,0.0031025123,0.003706085,0.0021733888,0.00009630922,0.00030526548,0.000024639583,0.0022753126],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9994894,0.000093213835,0.00013888792,0.00007619581,0.00009798723,0.00010429045],"domain_scores_gemma":[0.9984224,0.00071262446,0.0005453287,0.00007210937,0.000075343516,0.00017224309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039215296,0.00088732963,0.0009933232,0.0034427373,0.001519771,0.0012636653,0.0007557984,0.0035625375,0.0019519299],"category_scores_gemma":[0.0026215406,0.00048361256,0.0009591659,0.0033746073,0.0009429529,0.001670324,0.00089113356,0.0010760122,0.0006419641],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013701073,0.000024493802,0.0023912217,0.00042430512,0.000025275851,0.9922916,0.00019947847,0.00002722773,0.00040895544,0.00016587449,0.00056346087,0.0034644797],"study_design_scores_gemma":[0.000011246063,0.000030591345,0.00185195,0.00020126464,0.00004522048,0.9951749,0.00020065348,0.000072143754,0.00022831342,0.00014437924,0.0020312583,0.0000080013615],"about_ca_topic_score_codex":0.0010305734,"about_ca_topic_score_gemma":0.002577532,"teacher_disagreement_score":0.0035625375,"about_ca_system_score_codex":0.00063631433,"about_ca_system_score_gemma":0.00074943533,"threshold_uncertainty_score":0.0065298676},"labels":[],"label_agreement":null},{"id":"W44850464","doi":"10.1097/wnf.0b013e3180340319","title":"The Effect of Duloxetine on Primary Pain Symptoms in Parkinson Disease","year":2007,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Duloxetine; McGill Pain Questionnaire; Duloxetine Hydrochloride; Visual analogue scale; Parkinson's disease; Brief Pain Inventory; Rating scale; Medicine; Quality of life (healthcare); Physical therapy; Psychology; Disease; Chronic pain; Internal medicine","score_opus":0.017901058865947807,"score_gpt":0.3595551155893931,"score_spread":0.34165405672344534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W44850464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99290496,0.0055128275,0.00005368813,0.00012178685,0.000031782994,0.00006453589,0.00008539431,0.000014697731,0.0012102594],"genre_scores_gemma":[0.9974247,0.0017159552,0.00016613447,0.00013255683,0.00006221945,0.000032776934,0.000096711505,0.0000015591701,0.0003673842],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99985754,0.000054055097,0.000013799919,0.000011767,0.000031970863,0.00003081521],"domain_scores_gemma":[0.9997191,0.00009877081,0.00006837662,0.000008537273,0.000028244012,0.00007692535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019733925,0.00027459077,0.00073642365,0.000119659606,0.00018127493,0.00016596883,0.00018794199,0.0003404105,0.0021092833],"category_scores_gemma":[0.0007651311,0.00008373357,0.00025618516,0.00010632236,0.00016684008,0.00011626761,0.000082445025,0.0003578886,0.00018274084],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15320551,0.013619545,0.08115887,0.004814851,0.0017479311,0.0020523616,0.0004574968,0.0007776232,0.15598962,0.000113332,0.0032522727,0.5828105],"study_design_scores_gemma":[0.02722227,0.21041338,0.7425623,0.00022952651,0.0011439808,0.0029238912,0.00028665955,0.00112801,0.010400891,0.000097614466,0.0035578816,0.000033666394],"about_ca_topic_score_codex":0.0009864086,"about_ca_topic_score_gemma":0.0042731944,"teacher_disagreement_score":0.0021092833,"about_ca_system_score_codex":0.00020740357,"about_ca_system_score_gemma":0.00019151327,"threshold_uncertainty_score":0.007056296},"labels":[],"label_agreement":null}]}